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End-stage renal disease (ESRD) is increasingly a problem in the United States, and 
factors such as race/ethnicity and gender may not only worsen the risk of the disease but 
also correspond to worse treatment access. This is significant because ESRD is a heavy 
economic burden not only on patients, but on caregivers and the health care system, 
especially as disparities remain between different demographic groups. The purpose of 
this quantitative nonexperimental, historical, correlational design was to determine the 
extent to which gender and race/ethnicity predict 30-day readmission rates after 
hospitalization for ESRD patients. The theoretical framework for the current study was 
the theory of the determinants of avoidable readmissions in ESRD. The three research 
questions were to what extent patient gender predicts 30-day hospital readmission rate for 
ESRD patients, to what extent does patient race/ethnicity predicts 30-day hospital 
readmission rates, and are there any significant interactions terms in a combined 
prediction model using gender and race/ethnicity. Data were gathered from Data.gov and 
the United States Renal Data System. Regression analysis was used to analyze the data. 
The study found that gender, race, and income can all be predictors of ESRD 
hospitalization. The results have important implications for improving interventions to 
reduce ESRD hospitalization, thereby leading to positive social change by reducing both 












MBA, University of Phoenix, 2009 
BS, Interamerican University of PR, 1998 
 
 
Doctoral Study Submitted in Partial Fulfillment 
of the Requirements for the Degree of 









This study is dedicated to the loving memory of my mom Maria A. Perez for 
being the rock of our entire family and who inspire me to fight for a better quality and 
affordable care for ESRD patients. I also dedicate this study to my son Dylan Xavier, my 
fur baby Chloe, my Dad Juan, family, and friends for understanding the extended hours 
away from them and for encouraging to finish my doctorate, even I cannot spend time 
with them. To ESRD patients who suffer day to day to not have the best healthcare 




I would like to thank my Dissertation Chair Dr. Ronald Bucci and my committee 
member Dr. Miriam Ross for always giving remarkable feedback and direction. Special 
thanks for my URR Dr. Patrick Tschida for all guidance. With all of you I might not have 
done my Doctor of Healthcare Administration degree. I would also thank once again, to 





Table of Contents 
List of Tables ..................................................................................................................... iv 
List of Figures ......................................................................................................................v 
Section 1: Foundation of the Study and Literature Review .................................................1 
Introduction ....................................................................................................................1 
Problem Statement .........................................................................................................2 
Purpose of the Study ......................................................................................................3 
Research Questions and Hypotheses .............................................................................3 
Theoretical Foundations.................................................................................................5 
Nature of the Study ........................................................................................................5 
Literature Review Search Strategy ................................................................................7 
Literature Review Related to Key Variables and Concepts...........................................8 
Theoretical Framework ........................................................................................... 8 
Significance of End-Stage Renal Disease ............................................................. 11 
Complications and Comorbidities of End-Stage Renal Disease ........................... 16 
Treatments of End-Stage Renal Disease ............................................................... 19 
End-Stage Renal Disease and Hospitalization ...................................................... 23 
End-Stage Renal Disease and Demographics ....................................................... 28 
Methodological Precedents ................................................................................... 37 





Scope and Delimitations ..............................................................................................42 
Significance, Summary, and Conclusions ...................................................................43 
Significance........................................................................................................... 43 
Summary and Conclusions ..........................................................................................44 
Section 2: Research Design and Data Collection ..............................................................46 
Introduction ..................................................................................................................46 
Research Design and Rationale ...................................................................................46 
Methodology ................................................................................................................48 
Population ............................................................................................................. 48 
Power Analysis and Sample Size Estimation ....................................................... 48 
Sources of Data ..................................................................................................... 49 
Operationalization of Variables ............................................................................ 49 
Data Analysis ........................................................................................................ 50 
Research Questions and Hypothesis ............................................................................50 
Threats to Validity .......................................................................................................52 
Ethical Procedures ................................................................................................ 54 
Summary ......................................................................................................................54 
Section 3: Presentation of the Results and Findings ..........................................................56 
Research Questions and Hypotheses ...........................................................................57 
Methodology and Research Design ...................................................................... 58 
Data Collection, Sample, and Sampling Approach .............................................. 59 




Section 4: Application to Professional Practice and Implications for Social 
Change ...................................................................................................................71 
Introduction ..................................................................................................................71 
Theoretical Foundation ................................................................................................71 
Interpretation of the Data .............................................................................................72 
Interpretation of the Findings................................................................................ 72 
Limitations ...................................................................................................................77 
Recommendations ........................................................................................................78 






List of Tables 
Table 1. Descriptive Statistics for Gender, Race/Ethnicity, and 30-Day Readmission 
Rates After Hospitalization (Percentages) .............................................................57 
Table 2. Regression Results Using Row-Wise From Years 2007 to 2017, for Each 
Variable and Hospital Readmission Rates as the Criterion ...................................59 
Table 3. 2008-2017 Regression Analyses of Hypothesized Predictors of Hospital 
Readmissions Rates ...............................................................................................61 




List of Figures 
Figure 1. [Please add figure caption here] .........................................................................xx 





Section 1: Foundation of the Study and Literature Review  
Introduction 
End-stage renal disease (ESRD) is a serious problem today, affecting over two 
million people worldwide (Robinson et al., 2016). Although the condition has nearly 
plateaued in the developed world, the incidence is still slowly increasing. The United 
States alone sees over 120,000 new cases annually (Saran et al., 2017). ESRD is the fifth 
and final stage of chronic renal, or kidney, disease, at which point a patient’s kidneys 
have failed entirely. Treatment at this stage requires hemodialysis, an external filtration 
device that filters the patient’s blood in place of the kidney. The only cure for ESRD is a 
kidney transplant, and, at present, there is a significant disparity between availability and 
demand (Robinson et al., 2016). This disparity is especially present for minorities, even 
in developed countries. Of all chronic conditions, including cancer and heart disease, 
ESRD is the most likely to result in hospitalization (Lovasik et al., 2016). Unnecessary 
ESRD-related hospitalizations impose a high cost and represent the best way to 
simultaneously decrease ESRD costs and improve treatment (Matthew et al., 2015).  
The purpose of this quantitative nonexperimental, historical, and correlational 
design was to determine the extent to which gender and race/ethnicity predict 30-day 
readmission rates after hospitalization for ESRD patients. The study also examined 
interactions between these variables on the overall risk of ESRD-related hospitalization. 
The sample population was all adults with ESRD in the United States. The key variables 
were gender and race/ethnicity, 30-day readmission rates, and ESRD-related 




ESRD is increasingly a problem in the United States, with over 120,000 new 
cases in 2014 alone and over 660,000 total cases in treatment (Saran et al., 2017). The 
specific problem is that factors such as race/ethnicity and gender may worsen the risk of 
the disease (Crews et al., 2018) and correspond to worse treatment access (Patzer et al., 
2015). While ESRD diagnoses are increasing in general, the problem is that minorities, 
especially minority women, may be at high risk for poor outcomes. This problem is 
significant because ESRD is a heavy economic burden on patients, caregivers, and 
society (Wang et al., 2016). While mortality rates associated with the condition have 
declined in the past 2 decades (Collins et al., 2015), considerable disparities remain 
between different demographic groups, and for minority groups, these benefits have been 
less pronounced (Robinson et al., 2016).  
The predictors of ESRD are nuanced and may not also be appropriate for 
traditional modeling. For example, dividing patients into two age brackets of those above 
65 or 80, a common cutoff in medical research, provides an inaccurate depiction of 
ESRD risks (Krishnaswami et al., 2016). Additionally, many of the factors predicting 
worse than average ESRD outcomes may be psychosocial, such as Blacks having a lower 
rate of treatment compliance strongly associated with experiencing everyday racism 
(Savage, 2017). Additional research is needed to help ease the economic burden of ESRD 
by reducing readmission rates (Matthew et al., 2015). Such research will benefit from 
considering socioeconomic and other contextual factors (Newman et al., 2016), 
especially those that may contribute to or create race and gender disparities in treatment 
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and outcomes (Shah, Leonard et al., 2018). The need to better understand the roles of 
race and gender emerged as a pointed gap in the literature. Addressing this identified 
research gap is important to health administration because unplanned rehospitalizations 
are expensive, and the burden of that expense falls on both patients and the hospitals that 
treat them. Thus, reducing readmission rates is an important outcome for both practical 
and altruistic reasons. 
Purpose of the Study 
The purpose of this quantitative nonexperimental, historical, correlational design 
was to determine the extent to which gender and race/ethnicity predict 30-day 
readmission rates after hospitalization for ESRD patients. The study also examined 
interactions between these predictors on the overall risk of ESRD-related hospitalization. 
Thus, the independent variables were gender and race/ethnicity. Additionally, the 
dependent variables were 30-day readmission rates and ESRD-related hospitalization 
risk, respectively. I gathered the data from two different historical databases: the USRDS 
for the first set and Data.gov for the second. These data were readily and publicly 
available, allowing me to easily access them and then perform multiple regression and 
ANOVA analyses. The large, national datasets available ensure that meeting the 
minimum sample size requirements were easily achieved and exceeded.  
Research Questions and Hypotheses 
The following quantitative research questions guided the current study. For each 
research question, a null and alternative hypothesis was presented.  
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RQ1: To what extent, if at all, does patient gender predict 30-day hospital 
readmission rate for ESRD patients in the United States? 
H01: Patient gender does not predict 30-day hospital readmission rate for 
ESRD patients in the United States. 
H11: Patient gender predicts 30-day hospital readmission rate for ESRD 
patients in the United States to a statistically significant degree. 
RQ2: To what extent, if at all, does patient race/ethnicity predict 30-day hospital 
readmission rate for ESRD patients in the United States? 
H02: Patient race/ethnicity does not predict 30-day hospital readmission rate 
for ESRD patients in the United States. 
H12: Patient race/ethnicity predicts 30-day hospital readmission rate for ESRD 
patients in the United States to a statistically significant degree. 
RQ3: Is there a significant interaction between gender and race/ethnicity in 
predicting 30-day hospital readmission rate for ESRD patients in the United 
States? 
H03: There is not a significant interaction between gender and race/ethnicity 
in predicting 30-day hospital readmission rate for ESRD patients in the United 
States?  
H13: There is a significant interaction between gender and race/ethnicity in 





The current study's theoretical framework was the theory of the determinants of 
avoidable readmissions in ESRD proposed by Matthew et al. (2015). This theory 
characterizes the aspects contributing to avoidable hospital readmissions for ESRD 
patients and presents such factors as characteristics of the patient’s hospital stays, the 
hospital itself, the dialysis facility, the nephrologist and other care providers, and the 
existing payment structure. The current study drew on one specific aspect of this theory, 
focusing on the role of patient characteristics. However, the various determinants of 
avoidable readmission have complex interrelationships with one another (Matthew et al., 
2015). Therefore, a detailed understanding of this specific and perhaps foundational 
determinant of avoidable readmissions is important in further testing and developing this 
theory. Also, the theory’s proposition that many ESRD-related readmissions following 
hospitalizations are avoidable from a health administration standpoint represents one of 
the driving forces behind the current study. By identifying the causes of avoidable 
rehospitalizations, they may be better targeted with interventions to reduce them, 
benefitting both patients and hospitals.  
Nature of the Study 
The nature of the current study was that of a quantitative, historical, correlational 
design. Quantitative research is an approach that examines the world from a numerical, 
objective perspective (Bryman, 2016). Quantitative research is useful for examining 
issues that can be quantified, such as those for which there are existing, validated 
quantitative instruments to measure, or for understanding the nature of the relationships 
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between two or more variables (Bryman, 2016). Overall, the greatest benefit of a 
quantitative study is that the results are based solely on objective data measured using 
carefully validated instrumentation. The numerical or otherwise closed-ended nature of 
this type of data also means that quantitative research can practically process and analyze 
large sample sizes (Bryman, 2016). Because it uses larger sample sizes, quantitative 
research creates results that can be generalized, strengthened, and measured using 
statistical techniques, such as power analyses and confidence intervals. All of this made 
the quantitative approach a strong fit for the current study because I sought to examine 
the relationships between easily quantified and measured variables. All the predictor and 
outcome variables in the research questions—gender, race/ethnicity, and 30-day hospital 
readmission rate—were either quantitative by nature or easily assessed sociodemographic 
variables. Furthermore, all three of the research questions guiding the current study 
pertained to the nature of the relationship(s) between these variables, and, as the next 
section demonstrates, large datasets are available containing these data. 
Data for the study was drawn from two secondary sources: Data.gov and the U.S. 
Renal Data System (USRDS). Data for RQ1 to RQ3 were drawn from the dataset 
available through the USRDS. Therefore, for the present study I requested the use of data 
for the 2016-2018 period for Medicare patients. The relevant dependent variables were 
hospitalization and 30-day readmission, whereas the independent variables were 
race/ethnicity and gender. All these variables are available in the Medicare dataset as per 
the USRDS website. The USRDS does not, however, include preferred language data. 
Therefore, for this purpose, a dataset from Data.gov was utilized that contained data on 
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the preferred language of Medicare claimants for ERSD on an annual basis since 2016. 
From this dataset, I collected the dependent variable of hospitalization.  
Literature Review Search Strategy 
The purpose of this quantitative nonexperimental, historical, correlational design 
was to determine the extent to which gender and race/ethnicity predict 30-day 
readmission rates after hospitalization for ESRD patients. The study also examined 
interactions between these predictors on the overall risk of ESRD-related hospitalization. 
The following research questions guided the study:  
RQ1: To what extent, if at all, does patient gender predict 30-day hospital 
readmission rate for ESRD patients in the United States?  
RQ2: To what extent, if at all, does patient race/ethnicity predict 30-day hospital 
readmission rate for ESRD patients in the United States?  
RQ3: Are there any significant interaction impact between gender and 
race/ethnicity in predicting 30-day hospital readmission rate for ESRD patients in 
the United States?  
I reviewed the academic and medical literature to inform the study in answering these 
research questions. 
I carried out this literature search using Walden University Libraries. I used 
PubMed, Medline, and Google Scholar. Keywords utilized in the literature search 
included renal, kidney, hospitalization, demographic, ESRD, end stage renal disease, 
race, ethnicity, language barrier, epistemological triad, and appropriate combinations. 
After carrying out these searches, I examined the titles in the results. Based on the titles 
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that seemed relevant, I narrowed the literature search and reviewed the abstracts of those 
articles with promising titles. Based on this review of the abstracts, I ultimately selected 
the most relevant articles. All of these articles were recent sources from within the past 5 
years (2015-2019). All the sources chosen were from peer-reviewed scholarly journals, 
scholarly books, or dissertations. 
I divided the resulting literature into themes that served to support the study. The 
literature review begins with a more in-depth look at the theoretical framework for the 
study. Five key themes follow this theoretical framework. First is the significance of 
ESRD as a problem. Second, are the complications and comorbidities of ESRD. Third, 
are the treatments of ESRD. Fourth is ESRD and hospitalization. The fifth and final 
theme is ESRD and demographics. I also evaluated the importance of the key variables in 
this study. The independent variables were gender and race/ethnicity, whereas the 
dependent variables were 30-day readmission rates and ESRD-related hospitalization 
risk. 
Literature Review Related to Key Variables and Concepts 
Thus, the independent variables were gender and race/ethnicity. The dependent 
variables were 30-day readmission rates and ESRD-related hospitalization risk. 
Theoretical Framework 
The theoretical framework for the current study was the theory of the 
determinants of avoidable readmissions in ESRD proposed by Matthew et al. (2015). As 
will be further emphasized in the later section on ESRD and hospitalization, ESRD-
related hospitalizations, like all hospitalizations, are costly for both the patient and the 
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hospital. Overall, unnecessary hospitalization has a high societal cost and should be 
avoided where possible (Matthew et al., 2015). Some hospitalizations, especially for a 
chronic condition like renal disease, are not avoidable. However, many hospital 
readmissions are avoidable. Understanding the differences between avoidable and 
unavoidable hospitalizations and especially readmissions is a key idea in reducing the 
societal and individual costs of ESRD. As many ESRD patients are on Medicare for their 
treatment (Mu et al., 2018), these costs are far-reaching and significant. 
Matthew et al. (2015) sought to develop a framework that characterizes the 
aspects of treatment and its circumstances that define or contribute to avoidable hospital 
readmissions for ESRD patients. As per the theory, such relevant factors have significant 
breadth, including characteristics of both the patient’s hospital stay and the hospital itself, 
the dialysis facility, the nephrologist and other care providers, and the existing payment 
structure. The current study does not examine all these factors; instead, it is focused on 
one of the framework’s relevant dimensions: patient characteristics. As per Matthew et al. 
(2015), patient characteristics are far from the only factor that may drive avoidable, 
ESRD-related readmissions for patients, but they do represent one highly important set of 
factors. As per the theory, all these determinants of readmission are interrelated; 
therefore, studying even this single aspect may shed some light on broader issues. 
In particular, the patient characteristics and factors in this study may be deeply 
interrelated with treatment characteristics. As discussed later in the demographics section, 
many patient characteristics may affect both care quality and the places from which care 
is received, in addition to the likelihood of facing ESRD in the first place (Newman et al., 
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2016). Therefore, through Matthew et al.’s (2015) theory, the narrower results in the 
present study may link to the broader spectrum of issues causing ESRD hospitalization 
and avoidable readmissions. In practical terms, avoidable readmissions usually indicate 
either a failure of treatment on the part of the healthcare provider or a failure on the part 
of the patient to adhere to posttreatment self-care. Both factors can be avoided, but 
because of the interconnectedness, failure of treatment can also be related to patient 
characteristics, not merely to provider and care characteristics. For example, as per 
Savage (2017), if patients perceive bias or racism from their healthcare provider, they 
may be less likely to comply with posttreatment care directions, whereas that same tacit 
bias can also cause providers to offer poorer care (Phelan et al., 2015). 
Overall, therefore the Matthew et al. (2015) theory was the foundation of the 
current study. It provided not only a strong theoretical justification for the current study’s 
focus on patient characteristics but also suggested a broader theoretical context into 
which the current study fits. The current study does not exist in a vacuum, and the 
variables under consideration could likely never serve to characterize the problem 
entirely. By adopting a theoretical foundation that shows how those factors are related to 
other key determinants of avoidable rehospitalization, I contextualize the current study in 
the broader theoretical landscape. Furthermore, this theoretical grounding suggests the 
key outcome variable, that of ESRD-related 30-day rehospitalization, a choice that will 
be further supported by the later section that focuses on hospitalization specifically.  
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Significance of End-Stage Renal Disease 
ESRD is the final stage of a broader condition known as renal disease, kidney 
disease, or nephropathy (Cobo et al., 2016). Renal disease can be characterized broadly 
as either nephritis, which is inflammatory kidney disease, or nephrosis or 
noninflammatory kidney disease (Cobo et al., 2016). Regardless of whether a specific 
kind of renal disease is inflammatory or not, the ultimate effect is damage to the kidneys 
and the impediment of their health function. Chronic or long-term kidney disease 
progresses gradually, starting with no symptoms and developing significant symptoms 
over an extended period (Cobo et al., 2016); it is a chronic kidney disease that is 
generally under consideration in the case of ESRD.  
The human kidney’s main function in vertebrates as a whole is blood filtration 
(Krolewski et al., 2017). The kidney filters the bloodstream, catching waste and diverting 
it to the urinary tract to be expelled in urine. Accordingly, impaired kidney function is 
problematic because it prevents waste from being properly removed from the 
bloodstream, allowing it to build up to dangerous levels (Krolewski et al., 2017). Renal 
disease prevents or limits excess liquid expulsion from the body, marking significant 
kidney damage as quite dangerous. A precise medical definition of renal disease is 
somewhat more complicated and specific. As per Webster et al. (2017), the exact 
definition of the condition has changed and evolved, but the currently accepted 
international definition is “decreased kidney function shown by glomerular filtration rate 
(GFR) of less than 60 mL/min per 1·73 m2, or markers of kidney damage, or both, of at 
least 3 months duration, regardless of the underlying cause” (p. 1238). However, the most 
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common causes are diabetes and hypertension, though the leading causes also differ 
across differing contexts, such as in different ethnic groups (Webster et al., 2017).  
In the context of chronic renal disease, the end-stage is defined as the point at 
which natural kidney function has ceased mostly or entirely and must be partially or 
entirely replaced by external hemodialysis (Robinson et al., 2016). Hemodialysis, or 
dialysis, is a process in which a person’s blood is cycled through an external device, 
which replaces the kidney’s filtration function (Robinson et al., 2016). At this point, 
ESRD is a condition of extreme concern, especially in a worldwide context. ESRD 
affects over two million people worldwide, and it may have significant mortality in the 
global setting (Robinson et al., 2016). The specific mortality rates resulting from ESRD 
differ heavily based on the type of care available in a region and the population’s access 
to that care. In general, ESRD treatment with in-center hemodialysis is associated with a 
poor survival rate overall, though this is higher/longer in some Asian countries and parts 
of Europe (Robinson et al., 2016). Furthermore, ESRD poses the greatest risk of 
mortality soon after its onset, suggesting that those patients at this point fail to gain 
access to dialysis or to adjust their lifestyles to accommodate the need for it (Robinson et 
al., 2016).  
In the United States, renal disease is classified into five stages. Counting all these 
stages, about 15% (14.8%) of the United States population has chronic renal disease, with 
most of these being at stage three (Robinson, 2016). Even in the United States, ESRD 
testing is lower than ideal, with less than half (48%) of the population, even within 
Medicare participants, being properly screened for the condition. Even so, ESRD 
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incidence and diagnosis is increasing, with 120,688 new diagnoses in 2016, a 1.1% 
increase from 2015. Overall, ESRD rates are increasing at a faster rate, of 3.5% from 
2013 to 2014, with 678,383 total cases in 2014; however, this is somewhat encouraging 
because it suggests that there have also been significant decreases in ESRD mortality 
from better treatment. Indeed, relative to the rest of the world, the United States rates of 
ESRD are improving. Although they continue to rise, 1% is a relatively small growth. 
Thus, in affluent countries such as the United States and Japan, ESRD rates are 
stabilizing, relatively speaking (Wetmore & Collins, 2016). However, in poorer or 
otherwise developing countries, healthcare systems struggle with soaring rates of renal 
disease. These soaring rates of ESRD also contribute to a widening gap between the 
number of ESRD patients who can receive kidney transplants, the only effective cure, 
and the number of available kidneys (Wetmore & Collins, 2016). In terms of the causes, 
research supports that diabetes is the most common cause. Burrows et al. (2017) further 
attested to roughly 120,000 new cases of ESRD annually in the United States, and their 
analysis suggested that “among these persons, 44% (approximately 53,000 persons) had 
diabetes listed as the primary cause of ESRD (ESRD-D)” (p. 1165). Interestingly, 
however, the role of diabetes as a cause of ESRD has changed over time. Based on a 
retrospective analysis of ESRD data for the period 2000-2014, the incidence of diabetes-
related ESRD has decreased by about 33% (Burrows et al., 2017). This is an interesting 
shift and suggestive of either better control of the complications of diabetes or a more 
significant rise in other causes of ESRD. 
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Regardless of its cause, however, ESRD is significantly problematic. There are 
significant burdens associated with the condition, perhaps the foremost of which is 
financial. Indeed, ESRD creates high costs for multiple stakeholders, including patients, 
caregivers, and society (Wang et al., 2016). The growing trend in chronic kidney disease 
has made these economic concerns more important because they call into question the 
present capacity to manage these costs. This is especially true because the numbers of 
those struggling with ESRD are growing at both ends, with both an increase in diagnoses 
and an increased survival chance. ESRD is especially costly because the costs associated 
with the condition increase throughout disease progression, yet most research shows only 
the tip of the proverbial iceberg in that it looks at only direct costs of care (Wang et al., 
2016). Thus, the true extent of the cost of ESRD when indirect expenses are factored in is 
unknown. Indeed, only recently have new analysis techniques that are suited to large 
datasets been applied to ESRD data. As per Liao et al. (2016), cluster analysis is a data 
analysis technique that has been used to successfully analyze data in several fields, but 
rarely in healthcare data.  
The Liao et al. (2016) study was an exploratory attempt to apply this analysis 
technique to a relatively small cohort (roughly 19,000 patients) as a proof of concept for 
cluster analysis and k-mean grouping in medical expenses, ESRD. Their results 
suggested that expenses following the commencement of dialysis treatment are relatively 
stable in patients with a low number of comorbidities. In contrast, the researchers 
associated a high number of comorbidities with more unpredictable and often increasing 
costs following the beginning of dialysis (Liao et al., 2016). While a somewhat intuitively 
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obvious result, this did support the use of techniques of this sort to better understand the 
costs of ESRD. Nonetheless, this supports Wang et al.’s (2016) assertion that the overall 
costs of ESRD are poorly understood. 
This lack of understanding of the depth of the problem may be part of the reason 
for a dearth of research (Mendu et al., 2016). While significant academic research 
regarding ESRD exists, as this review evinces, Mendu et al. (2016) argued that this 
research is less than it could be. Specifically, they argued that as illustrated by this 
section, kidney disease should be considered a significant problem in the United States 
and that significant federal funding should be allocated. However, ESRD is 
underrecognized as a problem relative to other health conditions and therefore receives 
less research and funding than similarly prominent problems (Mendu et al., 2016). Some 
strong means to conduct such research already exist, however. The most prominent of 
these is the dataset that I used for the current study, the USRDS.  
Collins et al. (2015) reported recently on the history and significance of this 
massive dataset. The USRDS was created by the University of Minnesota in 1989. This 
original database only focused on the incidence and prevalence of ESRD. However, in 
2001, the Minneapolis Medical Research Foundation transformed this database into a 
more comprehensive source of information that includes a wide array of related topics 
such as disease severity, hospitalizations, pediatric populations, prescription drug use, 
and chronic kidney disease, and the transition to ESRD. Such data represents a rich 
source of data with which to conduct research. It should be noted that ESRD, in addition 
to its financial costs, has high costs in terms of quality-of-life (Raspovic et al., 2017). 
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Although these are more physical than mental, overall, having ESRD has been found to 
represent a significant decrease in terms of quality of life even for patients already 
suffering from a chronic condition such as diabetes, much less for those without one.  
Overall, therefore, ESRD is a significant problem on a global scale. In developed 
countries, such as the United States, ESRD incidence has plateaued in recent years, 
compared to its past growth. Nonetheless, some stage of renal disease affects nearly 15% 
of the United States population. ESRD can have significant consequences, including but 
not limited to death, high healthcare costs, and lowered quality of life. Therefore, 
research into ESRD should be a priority to determine how to best lower the still-high 
incidence of this expensive and dangerous condition.  
Complications and Comorbidities of End-Stage Renal Disease 
As per Mendu et al. (2016), one of the decisive factors in determining the cost of 
ESRD may be the comorbidities and complications it brings. Given that ESRD can be 
caused by two other significant chronic conditions, hypertension and diabetes, these 
diseases represent two important and dangerous comorbidities for ESRD. Diabetes is the 
cause of over 40% of ESRD, and thus the two conditions co-occur in nearly half of 
patients (Burrows et al., 2017). The most significant complication of ESRD is mortality. 
As of 2015, ESRD was the cause of death for 1.2 million people worldwide, a drastic 
increase in just 25 years; only about 400,000 died of ESRD in 1990 (Global Burden of 
Disease, 2016). Kidney failure without adequate dialysis treatment leads to almost certain 
death, as the body can no longer effectively filter waste out of the bloodstream. Even 
under dialysis treatment, the effectiveness of the treatment versus the rate of waste 
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accumulation may not be enough (Robinson et al., 2016). Furthermore, dialysis treatment 
often requires access to the facility and a consistent means of transportation and the 
dedication necessary to maintain a rigorous and highly time-consuming dialysis regimen. 
As a result, ESRD has a high mortality rate even in developed countries, where mortality 
is highest immediately following ESRD onset (Gillespie et al., 2015). Interestingly, 
despite the overall greater role of diabetes causing ESRD, significantly more ESRD 
deaths result from hypertension-caused ESRD (550,000 annually) than result from 
diabetic ESRD annually (420,000 annually; Global Burden of Disease, 2016) 
Another somewhat prominent comorbidity and one of the most important is that 
of cancer. Although not nearly as common a comorbidity as diabetes, which is strongly 
related as a cause of ESRD, cancer has important interactions with ESRD. Research by 
Butler et al. (2015) suggested that ESRD may be a potential cause of cancer, or at least 
that ESRD patients at an increased risk of cancer. Like the current study, the researchers 
in this study adopted an approach using historical ESRD Medicare data to conduct a 
quantitative retrospective cohort study of ESRD patients. They found that the 5-year 
incidence rate of any kind of cancer following ESRD and the onset of dialysis was 
9.48%. The results suggested that the incidence rates of certain common cancers 
increased, but others specifically decreased. Specifically, the incidence of kidney/renal 
pelvis cancer increased, while the risk of colon/rectum, lung/bronchus, and pancreas 
cancers decreased following the onset of dialysis treatment. Nonetheless, the overall 
association of cancer as a potential complication of ESRD is troubling, given the 
considerable additional cost and danger posed by cancer.  
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ESRD may be comorbid with or even a result of cancer, especially renal cancer 
(Nguyen et al., 2017). One specific mechanism of note in this regard is that cancer-
related ESRD may occur following surgery to remove parts of the kidneys that are 
malignant. Based on analysis of a historical dataset from 1983 to 2007, again using the 
same USRDS dataset that the current study adopted, Nguyen et al. (2017) examined the 
outcome of these cancer-related cases of ESRD. They found that patients with renal 
cancer-related kidney removal or surgery had significantly decreased survival rates 
relative to the average for ESRD. The study’s results must be examined in the context of 
general cancer-related dangers, which could decrease the survival chances of those with 
both ESRD and renal cancer. Nonetheless, this comorbidity was associated with a 
decreased life expectancy. Interestingly, relative to diabetic ESRD, patients with ESRD 
related to or resulting from kidney reduction or removal for non-cancer-related reasons 
was associated with increased life expectancy.  
Overall, ESRD has significant comorbidities and may be associated with 
significant complications. Being as diabetes and hypertension are the main causes of 
ESRD, they are also its most pronounced comorbidities. However, there are other 
significant comorbidities, such as lupus erythematosus and renal cancers. Some of these 
comorbidities, such as lupus erythematosus, have significantly different patterns of 
occurrence based on gender, ethnicity, and other gendered factors. The most prominent 
complication of ESRD is death; ESRD is a quite lethal condition if not treated promptly 
and consistently. In addition, ESRD may result in other complications such as foot ulcers, 
lower-extremity amputation, and renal cancer. Overall, cancer has a high incidence in the 
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5 years following an ESRD diagnosis, especially renal cancer. Conversely, ESRD 
resulting from renal cancer and its treatment is especially deadly.  
Treatments of End-Stage Renal Disease 
As noted in the previous section, prompt, and consistent treatment of ESRD is 
completely necessary to avoid mortality. As ESRD represents the point of essentially 
total kidney failure, the minimum treatment necessary is hemodialysis, an external, 
artificial filtration process that replaces the kidneys' function. Although not as effective as 
a real kidney, dialysis is a functional treatment. However, the only true cure for ESRD is 
a kidney transplant (Wetmore & Collins, 2016). Unlike many other organs, kidney 
transplants are relatively unique in that, because a person can function acceptably well 
with a single kidney, kidney transplants need not be taken from deceased donors (Shah et 
al., 2016). Instead, a living donor can give a kidney and both the donor and recipient can 
function with a single kidney in place.  
Nonetheless, there is a significant gap between transplant availability and 
transplant demand. This gap is even broader in the developing world, as ESRD incidence 
rates increase significantly faster than the rates of those receiving renal replacement 
therapy (Wetmore & Collins, 2016). As with other aspects of ESRD, demographics play 
a role in transplantation. Minority patients have a significantly higher presence on kidney 
transplant waitlists and represent a significantly lower portion of the donor pool 
(Newman et al., 2016). The reasons for these disparities are complicated and beyond the 
scope of the present study, but the existence of the disparities themselves is highly 
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problematic. Even in terms of simpler treatment such as dialysis, however, the existing 
literature suggests several important issues. 
One such result, by Gillespie et al. (2015), suggested the importance of prompt 
care even more strongly. In their study, Gillespie et al. (2015) examined the relationship 
between a prior history of nephrology—care by a kidney doctor—and mortality in newly-
diagnosed ESRD patients. As with much other research, their study drew upon the 
USRDS as a data source and included nearly half a million patients between 2006 and 
2010. Their results indicated that “overall, 33% of new ESRD patients had received no 
prior nephrology care, while 28% had received care for >12 months” (p. 772). The low 
incidence of care prior to reaching the end stage is troubling in that it suggests patients 
fail to achieve any specialized care, which might have prevented their renal disease from 
advancing to stage five. However, those who had no prior nephrology care were also at 
significantly higher risk of first-year mortality; conversely, pre-existing nephology 
treatment was not only associated with better survival rates but a host of other positive 
outcomes, including the discussion of transplantation options.  
Another study, by Cervantes et al. (2018), emphasized the importance of prompt 
and consistent dialysis treatment. Their study was concerned with the plight of 
undocumented immigrants, who may at present only receive dialysis treatment on an 
emergency basis. Their study compared the results of receiving dialysis three times a 
week to receiving it on an emergency-only basis. This study also adopted a retrospective 
cohort study, though a smaller-scale one that included data from only three hospitals from 
2007 to 2014. As expected, the results of their analysis indicated that there was a higher 
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mortality rate for those who only received dialysis on an emergency basis. However, the 
magnitude of that difference was still quite striking, with 5-year mortality for those 
receiving only emergency dialysis being a staggering 14 times higher. In each case, the 
population was similar, being undocumented immigrants. These results strongly bear out 
the importance of consistent dialysis treatment for those with ESRD and suggest that an 
emergency-only treatment basis is not, in practical terms, a feasible strategy.  
Another issue of interest is blood pressure control during treatment. Given that 
hypertension is the most lethal cause of ESRD, blood pressure control during dialysis has 
traditionally been a tenet of ESRD treatment (Ku et al., 2015). However, this guideline 
has been an issue of some contention amongst doctors because randomized control trials 
have, thus far, failed to demonstrate significant effects, but strict blood pressure control 
during this period could have more tacit implications in the long term. Accordingly, to 
examine this, Ku et al. (2015) used the USRDS to follow up on patients from a 1989-
1993 study of renal disease and blood pressure control. Although the original study had 
failed to show any significant effect of blood pressure control on renal disease 
progression, the follow-up study found that there was a significant reduction to long-term 
mortality risk, with a roughly 25% lower risk of mortality in the strict blood pressure 
control group as compared to the treatment group.  
Finally, offering some contextualizing research, Patzer et al. (2015) studied the 
state of ESRD treatment in the state of Georgia. They conducted a historical analysis of 
ESRD treatment in the specific context of Georgia, an analysis which included 279 
patients of ages 18-69 from 308 facilities over the period 2005-2011. In Georgia, the 
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government requires dialysis centers to inform their patients of all treatment options, 
including that of transplants, and that beginning the consideration process generally 
requires a referral from a dialysis center. Accordingly, referral for transplantation from a 
dialysis center has practical importance for treatment (Patzer et al., 2015). In Georgia, the 
factors associated with centers being unlikely to refer patients for transplantation were 
high-poverty. A higher patient to social worker ratio, and non-profit status for the dialysis 
center and older age or white race for patients. However, these factors were not 
necessarily indicative of patients’ odds of being waitlisted for a transplant. Overall, the 
results of this study indicated that dialysis center referrals play an important part in 
moving patients to waitlists, but that this may not be the decisive factor. 
In general, the treatments for ESRD are hemodialysis and kidney transplants. 
Hemodialysis is a necessary treatment and represents an external facility being used to 
filter a patient’s blood of waste in place of natural kidney function. This treatment does 
not do anything to alleviate the condition itself, only to keep it from being fatal. The only 
cure for ESRD is transplantation, also known as renal replacement therapy. 
Transplantation is an effective cure in the sense that both the donor and recipient in a 
kidney transplant can survive with only a single kidney. This means that kidney donation 
is one organ transplant that doctors can do from living donors and deceased donors. Some 
recent advancements, such as a wearable artificial kidney, offer the intermediate 
possibility of a better quality-of-life than full hemodialysis without a transplant, but these 
technologies are still forthcoming. Preexisting nephrological care can predict better 
overall outcomes and survival in ESRD patients, and dialysis centers play an important 
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role in referring patients for transplantation. As alluded to in previous sections, however, 
there remains a significant gap between kidney transplant waitlists and available donors.  
Significance of Treatment to the Study 
Overall, increased quality of ESRD care is the outcome of the study. This variable 
takes the form of 30-day rehospitalization, as discussed in the following section because 
reducing avoidable rehospitalization is one of the best measures of improves ESRD care 
(Matthew et al., 2015). However, this is merely one practical outcome that is broadly 
indicative of treatment quality and not the only one. Accordingly, the discussion of 
overall ESRD treatment is not only in its importance as background information and how 
it contextualizes hospitalization but also in shaping and characterizing the broader field of 
treatment. For example, one reason why ESRD care may falter or fail relates to the self-
care component. Studies such as that of Ku et al. (2015) illustrate this by demonstrating 
the long-term effects of self-care aspects such as blood pressure control on long-term 
ESRD outcomes. The value of prior nephrology care (Gillespie et al., 2015) also supports 
the importance of communicating with and educating patients as a key part of ESRD 
treatment,  
End-Stage Renal Disease and Hospitalization 
As with many chronic and deadly conditions, hospitalization is a potential 
consequence of ESRD. Hospitalization involves a patient being admitted to a hospital and 
kept overnight for treatment (Matthew et al., 2015). Hospitalization is vastly expensive. 
Lengthier hospital stays may also lead to complications such as bedsores, blood clots, or 
muscular atrophy. Therefore, avoiding hospitalization where possible is desirable. 
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Although most dialysis treatment is undertaken, at present, in outpatient clinics that may 
or may not be associated with a hospital, outpatient treatment of this type is not 
considered hospitalization; only inpatient treatment is germane to this section.  
Inpatient hospitalization is the primary dependent variable in the current study for 
several reasons. Firstly, as per Matthew et al. (2015) and the theoretical framework, 
avoidable hospitalization and especially avoidable readmission are common in ESRD 
patients relative to the general population. Rehospitalization creates significant personal 
(Matthew et al., 2015) and societal (Liao et al., 2016) costs associated with ESRD. 
Therefore, short of reducing ESRD incidence, reducing ESRD-related hospitalization is 
likely the most effective way of diminishing the costs associated with the condition. 
Secondly, many hospitalizations associated with ESRD are avoidable with better 
treatment or better patient treatment adherence (Matthew et al., 2015). Better treatment 
adherence makes reducing avoidable hospitalizations—and especially unnecessary 
rehospitalizations—a priority as it suggests that reducing hospitalizations could be 
associated with an improvement in care and patient outcomes instead of merely treated as 
a cost-saving or practical measure. Third, as the following studies—and the following 
section—demonstrate, hospitalization for ESRD disproportionately affects certain 
groups. The outsized impact of ESRD on minority groups is both a reason to help remove 
the problem and a potentially helpful tool for so doing. In identifying these groups that 
are especially at risk, as the current study aims to do, it should be possible to develop 
interventions that target at-risk groups and improve their ESRD hospitalization outcomes.  
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Indeed, ESRD patients have the highest hospitalization rate for patients with any 
chronic illness, even including heart disease and cancers (Lovasik et al., 2016). This 
translates into extensive emergency room usage, and emergency room visits are an 
especially costly form of hospitalization. Examining these issues, Lovasik et al. (2016) 
conducted a historical study of all Medicare patients in the USRDS from 2005 and 2011 
concerning emergency room utilization. Somewhat confounding the data, researchers 
have found that some patients use the emergency room as a primary dialysis provider, 
with over 50 visits in the first year. These patients were removed from the dataset. The 
total resulting sample size was 769,228 patients, of which over 550,000 had at least one 
emergency room visit in the study period. Furthermore, 55% of the sample had at least 
one the first year following their ESRD diagnosis, and on average, patients had between 
two and three emergency room visits annually in their first 3 years of ESRD. As per the 
study, 
factors associated with higher rates of ED [emergency department] use included 
younger age, female sex, black (vs white) race, comorbid medical conditions, 
Medicaid insurance (vs Medicare alone), catheter or graft hemodialysis access (vs 
fistula), tobacco use, institutionalization, and more recent ESRD diagnosis. 
(Lovasik et al., 2016, p. 1563) 
The results quoted above provide further support for the idea that certain patients 
are more likely to need hospitalization, and this extensive usage of expensive emergency 
care suggests that hospitals could make considerable improvements in that dimension of 
ESRD. On the other side of the issue, the results of a study by Goodrich, Schaubel, 
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Smith, Merion, and Sharma (2016) demonstrated why a better understanding of ESRD 
hospitalization and avoiding rehospitalization might be especially important to patients 
with certain comorbidities, in addition to specific demographics. The Goodrich et al. 
(2016) study explored ESRD-related hospitalizations for patients with a liver transplant 
in addition to their ESRD. The study was historical in nature, including a matched sample 
of liver transplant patients with and without ESRD, for a total of 7,019 patients. The 
average hospitalizations per year were seven for liver transplant patients without ESRD 
and 23 for those with ESRD. Goodrich et al.’s analysis showed that, after adjustment for 
various covariates, the risk of hospitalization was 97% higher for liver transplant patients 
with ESRD than without it. While these hospitalizations are unlikely to be preventable, 
improved interventions could likely do much to equalize these figures. 
Finally, another interesting effect of ESRD on hospitalization pertains to the use 
of hospice care. Hospice care represents a form of end-of-life care in which patients who 
have accepted the onset of death are cared for. Many patients suffering from chronic 
conditions utilize hospice care. Despite their increased use of standard hospitalization, 
ESRD patients are less likely to use hospice services than are patients with other chronic 
conditions (Goodrich et al., 2016). The results of a historical study examining the usage 
and costs of hospice for ESRD patients found that those patients who stayed in the 
hospice less than 3 days, around 40% of the historical cohort, were less likely to die in 
the hospital or in intensive care, but they had similar end of life costs. However, these 
short stays were also associated with a higher chance of hospitalization. Overall, longer 
hospice stays were associated with progressively less overall hospice costs and intensive 
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procedures. Overall, end-of-life costs were quite similar, however, suggesting that there 
may be no clear advantage in this context. 
Overall, ESRD is the chronic condition most likely to lead to a patient’s 
hospitalization, even compared to heart disease or cancer. Hospitalization, in the case of 
ESRD represents a large part of its personal and societal costs. Therefore, reducing 
hospitalization—and especially unnecessary rehospitalization—is likely the best way to 
decrease the costs associated with ESRD while at the same time offering the chance to 
improve care. ESRD hospitalization is also significantly more pronounced for certain 
demographic groups and patients with certain comorbidities. ESRD patients also make 
considerable use of emergency services, with most ESRD patients visiting the emergency 
room in their first year of the condition and having multiple visits annually in the first 3 
years. All of this indicates that hospitalization—and especially unnecessary 
readmission—is the appropriate dependent variable for the current study and one of the 
most important outcomes to target and reduce after ESRD incidence.  
30-Day Readmissions 
The specific variable of 30-day readmission is considered a measure of the 
success or failure of treatment’s effectiveness during the first hospitalization (Matthew et 
al., 2015). Thus, 30-day readmission represents a measure of the issues associated with 
hospitalization. Sometimes, ESRD hospitalization is unavoidable (Matthew et al., 2015). 
In general, however, another such unavoidable episode is unlikely to happen within 30 
days of the first (Matthew et al., 2015). Accordingly, by measuring 30-day readmission, 
the study is effectively measuring the quality of the ESRD care provided in the first 
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hospitalization. While overall hospitalization might be another possible way of thinking 
about this variable, the unavoidable hospitalizations associated with ESRD would skew 
this in areas with a higher incidence of ESRD. As the following section will demonstrate, 
gender may have correlates in both the severity of renal disease progression and the types 
of care provided. These are not the issues under study, but rather how ESRD care can be 
improved, especially through avoiding unnecessary readmission. Because most avoidable 
ESRD-related hospitalizations take on the form of readmission as per the theoretical 
framework (Matthew et al., 2015), 30-day readmission is the best way to measure 
hospitalization as it pertains to and is indicative of qualify of ESRD care.  
End-Stage Renal Disease and Demographics 
As alluded to in multiple prior sections, demographics play a key role in multiple 
aspects of ESRD. Demographics shape the rates of ESRD incidence, the rates of ESRD 
hospitalization (Lovasik et al., 2016), the likelihood of being referred for renal 
replacement therapy (Patzer et al., 2015), and many other aspects of ESRD. For this 
reason, most of the key predictors and independent variables in this current study are 
demographic in nature. The existing research indicates the importance of these variables 
as predictors of ESRD incidence and outcomes. 
Age 
As with many—if not most—chronic conditions, ESRD incidence is affected by 
age. However, traditional approaches to mapping the relationship between ESRD and age 
have critical shortcomings. Specifically, as per Krishnaswami et al. (2016), most such 
analyses dichotomized age into younger and older groups, where researchers categorized 
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ESRD patients at age 65 years and older, 80 years and older, or both and treated this 
overall in a linear fashion. Grouping by age is a somewhat natural approach if one wishes 
to encapsulate age into a variable but may not be an accurate reflection of the true effect 
of age on ESRD outcomes. The results of these studies often fail to make sense for 
revascularization, although they do predict ESRD mortality acceptably well. 
Krishnaswami et al. (2016) found that different arbitrary age cutoffs produce different 
results and that a linear model of age could not predict repeat revascularizations. 
However, a cubic spline model of age’s effects resulted in an improved model for age and 
a consistent revascularization model. The results of this model’s use suggest how simple 
and straightforward demographics categorization can result in more interesting data than 
expected. Because of this result demonstrating age weakness as a linear predictor, age 
was not chosen as a predictor in the current study. 
End-Stage Renal Disease and Ethnicity 
Race/ethnicity is another factor that strongly affects ESRD and related factors 
(Lovasik et al., 2016). Interestingly, race does not only predict outright outcomes but also 
the effects of other predictors. For example, dietary acid load is an important factor in 
predicting the development of kidney disease and its progression over time (Crews et al., 
2018). While this is true in general, a large study by Crews et al. (2018) found that this 
relationship holds to a significantly higher degree amongst Blacks than it does amongst 
Whites. This result is interesting in that it suggests even the progression through the 
various stages of renal disease may be significantly different across racial lines. However, 
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a considerably larger body of research demonstrates more direct links between race and 
ESRD.  
However, more directly relevant to the current study is that race and ethnicity—
alongside other demographic factors—can have effects through the availability and 
quality of care. Race and poverty were central to a study by Nee et al. (2017) on the role 
of pre-ESRD nephrology care. Patients who have access to nephrology before 
researching the ESRD are significantly associated with lower mortality and morbidity 
from ESRD, as per prior research (Gillespie et al., 2015). Based on a retrospective cohort 
study using a USRDS sample of 739, 537 patients from 2007-2012, Nee et al. (2017) 
found two independent results: those in poverty, as measured by Medicare and Medicaid 
eligibility, were significantly less likely to have undergone pore-ESRD nephrological 
care and that both Blacks and Hispanics, relative to Whites, were significantly less likely 
to have undergone pre-ESRD nephrological care. As per Gillespie et al. (2015), this puts 
the impoverished and these racial minorities at greater risk for first year mortality. Thus, 
overall, the race/ethnicity variable in the current study are supported by these results.  
Another highly relevant result stemmed from Shah et al. (2018) 's research, who 
studied gender, ethnicity, and access to hemodialysis care. As noted previously, access to 
dialysis on a regular basis can decrease the risk of mortality up to 14 times relative to 
emergency-only access (Cervantes et al., 2018). However, different types of hemodialysis 
access have different outcomes as well; specifically, “Arteriovenous (AV) access confers 
survival benefits over central venous catheters (CVC) in hemodialysis patients” (Shah et 
al., 2018, p. 4). Based on another retrospective cohort study comprising 885,699 
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participants from 2004 to 2014, Shah et al. (2018) found that women have significantly 
lower odds of having access to advantageous arteriovenous dialysis. Racial results were 
more mixed: Blacks and Asians were more likely to use arteriovenous access than were 
Whites, but Hispanics were less likely to. Given that the type of dialysis access patients 
has conferred clear benefits in terms of their treatment, the results of Shah et al.’s (2018) 
study offers significant support for the use of race and gender as predictors of ESRD 
treatment outcomes.  
More directly touching upon hospitalization was a study by Newman et al. (2016). 
Specially, their research examined racial differences in hospitalization hos patients on 
kidney transplant waitlist (for the deceased donor waitlist, in particular). The study 
represented another example of a retrospective cohort study using USRDS data, with a 
sample of 24,581 patients between 2005 and 2009. The researchers adopted a novel 
cluster analysis approach and found that, based on the results, patients who were 
hospitalized were less likely to receive transplants, and Blacks and Hispanics were more 
likely to be hospitalized than were Whites. However, they noted that adjusting for the 
role of hospitalization in determining the likelihood of being given a kidney transplant 
did not significantly reduce the level of disparity on the waitlist itself. These results 
encapsulate two important ideas relevant to this study. Firstly, the fact that hospitalization 
decreases an ESRD patient’s chances of being given a kidney transplant represents 
another reason supporting the importance of hospitalization as an outcome to be reduced. 
Secondly, the results provide strong support for the use of race as a primary demographic 
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predictor of hospitalization, as their results found that minorities were significantly more 
likely to undergo ESRD-related hospitalization. 
Considering all of this, one final study of interest is less statistical and more 
patient-centric. Black ESRD patients tend to have a significantly higher chance of non-
adherence to treatment guidelines (Savage, 2017). The outsized impact on Black ESRD 
patients is troubling in that it suggests an already disadvantaged demographic may act to 
make their own situation worse. Noting this, Savage (2017) sought to study the reasons 
why and used a mixed-methods approach that combined qualitative interviews and 
quantitative survey research. The study included 46 Black ESRD patients, 27 of whom 
participated in in-depth semi-structured interviews. Thus, although the sample size was 
not large enough to create significant quantitative effects, the qualitative results remain 
strong. The mixed-methods analysis overall suggested that the reason for this problematic 
non-adherence can be characterized as a response to perceived racism. Rather than 
explicit, high-level racism, the study participants characterized their experiences with the 
medical community as being affected by “everyday racism,” a low-level but pervasive 
type of racism. This experience of racism served to diminish the participants’ perceptions 
of the medical establishment, resulting in decreased attention to guidelines and resulting 
in non-adherence to those guidelines. This result suggests that racial differences in 
treatment may stem from more than simple racial predispositions. This principle may 
potentially extend to other demographic factors as well. 
Overall, there is no lack of evidence for the importance of demographics in 
shaping ESRD and, more relevantly, ESRD treatment, and treatment outcomes. The most 
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prominent demographic in the results was race/ethnicity, a demographic that occurred in 
almost every study. Thus, there is clear and strong support for race as an independent 
variable in the current study. Gender and poverty/employment were also supported as 
lesser predictors of ESRD outcomes and this germane to the study as independent 
variables. Age was also supported as a predictor of ESRD-related outcomes. However, 
the support for age occurred in such a way as to make it evident that age was not a 
variable well served by use as a linear predictor, as it would be in the present study. 
Therefore, age was not included in the current study. Finally, one study (Savage, 2017) 
gave insight into how even low-key perceived discrimination based on a demographic 
factor, such as race, can significantly affect treatment outcomes for that demographic by 
creating treatment guideline nonadherence. Such nonadherence is problematic and may 
result in significantly worse treatment outcomes, contributing to unnecessary hospital 
readmission.  
End-Stage Renal Disease and Gender 
Gender is a significant predictor of ESRD-related outcomes. This has already 
been referenced in several of the studies discussed above, but this section will provide a 
further specification of the prior results regarding gender. One such result is that of a 
study by Shah et al. (2018), which focused on the differing access of different 
populations to different treatment types. Their results indicated that women have 
significantly lower odds of having access to the advantageous arteriovenous dialysis. The 
lack of access to dialysis means that the treatment outcomes for women with ESRD may 
differ from those of men, which may affect the rate of ESRD-related (re)hospitalization. 
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Another study by Shah, Thakar, and Leonard (2018) found similar structural results of 
gender on ESRD outcomes. Specifically, using a sample of nearly 50,000 ESRD patients 
from the USRD, they found that women are, overall, 6% less likely than are men to be 
given enough information about kidney transplantation, thereby significantly effecting 
the quality-of-care provision.  
On the other hand, an analysis by Neugarten and Reckelhoff (2015) of prior 
research suggested that there are sex differences in the incidence and progression of 
kidney disease across multiple animals. In general, the researchers found that ESRD was 
more common in male animals but that they could easily replicate this outcome using 
hormonal treatments. The results suggested that sex hormones, rather than differences in 
the physical structure of the two genders, is likely responsible for gendered differences in 
ESRD (Neugarten & Reckelhoff, 2015) 
There is evidence for gender as an important variable; therefore, from both a 
social standpoint and a medical one, gender significantly impacts ESRD outcomes. 
Interestingly, these social effects on treatment disadvantage women, who receive worse 
types of care and worse information about care. Conversely, research suggests that—
based on multiple animal models—men are more medically at risk from ESRD and more 
likely to develop it due to sex hormones. These two effects work at cross-purposes to one 
another, making it not immediately apparent which gender should be expected to be a 




No studies explicitly address employment status. Instead, employment status is 
something of a proxy for another that is highly relevant: poverty. It is impossible to 
establish poverty based on the USRDS data that will be utilized in the current study. 
However, unemployed people are at a significantly higher risk for poverty, making 
employment status the closest reasonable proxy for poverty available in the data. Results 
for the importance of poverty are as follows. Patzer et al. (2015) found that impoverished 
patients are significantly less likely to be referred for a kidney transplant in Georgia. 
Given that transplants are the only true cure for ESRD, and transplants require a referral 
from a dialysis center, this indicates that the impoverished may have significantly lower 
access to a cure for ESRD. The lowered access to cures in turn, may put the impoverished 
at greater risk of hospitalization and poor treatment outcomes from ESRD. 
Nee et al. (2017) found that the impoverished are significantly less likely to have 
to experience pre-ESRD nephrology care during the progression of their kidney disease. 
Considering that pre-ESRD nephrology is significantly associated with improved patient 
outcomes and a lack thereof is related to significantly higher rates of first-year ESRD 
mortality, this suggests that the impoverished are likely to have poor treatment outcomes. 
Poor treatment outcomes may also suggest that the impoverished are significantly less 
likely to be knowledgeable about ESRD care and that they, therefore, may have worse 
self-care outcomes in following treatment guidelines following hospitalization.  
While employment status is likely not the best proxy for poverty, it is the best 
available in the USRDS dataset. Poverty has been significantly linked with at least two 
36 
 
different outcomes that predict worse treatment: a lack of transplant referrals and a lack 
of pre-ESRD nephrology care. Therefore, there is reason to believe that poverty—
measured through employment status—may significantly affect ESRD hospitalization 
and quality of care.  
Spoken Language 
Studies such as those of Gillespie et al. (2015) and Nee et al. (2017) illustrate the 
vast importance of patient-caregiver interaction and patient education. Both studies 
indicate that something as simple as a prior history of nephrology care can significantly 
impact patients’ likelihood of dying from ESRD. Indeed, the extra mortality from those 
without a history of nephrology care comes especially in the first year, suggesting further 
the role of the educational aspect of such care in preventing poor treatment outcomes. 
Furthermore, Savage (2017) demonstrated the importance of patients’ willingness to 
cooperate in their own care, noting how even the perception of everyday racism can make 
patients likely to disregard their treatment guidelines.  
While none of these directly indicate language as a barrier, they do indirectly 
suggest it. Patients whose preferred spoken language is not English may struggle to 
receive treatment instructions or fail to fully understand those treatment instructions even 
when they think they do understand them. Furthermore, most of those who would prefer a 
spoken language such as Spanish are at risk for the kind of everyday racism addressed by 
Savage (2017) over language and race/ethnicity. While indicating a language other than 
English as a preferred spoken language does not guarantee a language barrier, it is 
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strongly suggestive of one, and existing research suggests several reasons why such a 
barrier may be significantly related to ESRD treatment outcomes.  
Methodological Precedents  
The primary discussion of the study’s methodology and the justifications for it 
will be in section two of this document, which focuses exclusively on methodological 
issues. However, one methodological aspect that is more in the domain of the literature 
review is to examine the types of research methodology used by prior studies. This 
examination of methodological precedent provides a look at how similar studies have 
been undertaken in the past, thereby strengthening the case for adopting an approach that 
is “tried and true” as it were. In this study, the proposed research method is that of a 
nonexperimental historical, correlational design, also called a retrospective cohort study. 
The current study will draw its data from the USRDS, a large database of renal data. 
As previously alluded to, this methodological approach has a highly significant 
precedent. Of the studies included in this review, a majority adopted this same approach. 
Butler et al. (2015) used the USRDS dataset to analyze cancer risks in ESRD patients. 
Like the current study—and most of those following— Butler et al. (2015) limited their 
data to the data of Medicare patients in the USRDS because this subset of the data 
contains considerably more complete data than does the overall USRDS dataset. Collins 
et al. (2015) also used the USRDS—indeed, their study focused on an analysis of the 
dataset’s history and advantages. Gillespie et al. (2015) also utilized the USRDS, with a 
cohort of 443,761 patients, to study the relationship between a history of nephrological 
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treatment and ESRD mortality. At the time of publication, their study represented the 
largest cohort study of ESRD. 
Gómez‐Puerta et al. (2015) used a USRDS dataset to analyze the comorbidity of 
ESRD and lupus erythematosus. Even this much more specialized study was able to find 
a cohort of over 12,000 participants in the USRDS. Similarly, Kaminski et al.’s (2015) 
study of ESRD and foot-related complications used a USRDS cohort of over 45,000. Ku 
et al. (2015) adapted USRDS data for a more specialized purpose. Specifically, they used 
the data to follow up on the patients who had been involved in a clinical trial of blood 
pressure control and determine that, even though the trial had yielded no immediate 
results at the time, the two arms had different long-term outcomes. Liao et al. (2016) 
found the USRDS an ideal setting for a study that was designed to apply a novel big data 
analysis approach in healthcare.  
Lovasik et al. (2016) also used a USRDS cohort to study emergency room 
utilization by ESRD patients. In another study about the implications of prior nephrology 
care, Nee et al. (2017) mustered a cohort of over 700,000 patients from the USRDS data. 
Newman et al. (2016) drew upon a much smaller cohort of 24,000 to assess 
hospitalization and race. Perhaps the largest USRDS cohort used was 1.3 million patients 
in Nguyen et al.’s (2017) study of renal cancer. This list is not exhaustive, but already 
considerable. A few of the other reviewed studies that did not draw upon the USRDS 
dataset still adopted retrospective cohort designs using different and smaller data sources. 
Given its size, availability, and the completeness of its data for a large portion of the 
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population (Medicare patients), the USRDS and the cohorts it makes available for study 
are ideal for most quantitative analyses about ESRD.  
Research Gap 
The primary impetus for this study lies in its practical significance. As per the 
theoretical framework (Matthew et al., 2015), unnecessary and avoidable readmissions 
represent a significant source of expense for ESRD patients and society. ESRD is a 
chronic condition with the highest risk of hospitalization (Lovasik et al., 2016). There are 
significant racial disparities in both the incidence and treatment outcomes of ESRD. 
These practical issues, however, are not the only motivation for the study.’ Instead, they 
are parallel to an academic research gap, which also serves as a secondary motivation for 
the study. 
Three calls for further research highlight this research gap. First and foremost, of 
these is the call by Matthew et al. (2015). In keeping with the theoretical framework of 
the current study, this calls for further research highlighted the need for more research 
into the factors predictive of unnecessary ESRD-related hospital readmission to better 
target interventions to reduce the incidence thereof. Secondly, tying into this was a call 
for research by Newman et al. (2016) for such future research on further social context 
factors and their impact on ESRD treatment outcomes such as hospitalization. From this 
call for research, the current study will adopt the contextual factor of employment status 
and the other demographic variables chosen in concert with the literature review. The 
final call for research was for research into factors that may contribute to or create race 
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and gender disparities in treatment and outcomes (Shah et al., 2018). To answer this call 
for research, the current study will focus on the role of these demographic predictors. 
Summary 
In conclusion, this literature review examined the study’s theoretical foundations 
and five key themes. These themes were the significance of ESRD as a problem, the 
complications, and comorbidities of ESRD, ESRD treatments, ESRD and hospitalization, 
and ESRD and demographics. This review highlighted many aspects of ESRD. The 
condition is the fifth and final stage of chronic kidney disease, and ESRD rates are 
stabilized but still slightly increasing in the developed world, while incidence is rampant 
in the developing world. ESRD is often caused by diabetes and hypertension and may 
lead to renal cancer complications, which has a nearly 10% incidence in the 5 years 
following ESRD. A kidney transplant is the only cure for ESRD. Failing that, ESRD is 
treated by hemodialysis, in which an external device takes over the kidney’s function of 
filtering waste out of the bloodstream. 
Of chronic conditions, ESRD is the most likely to cause hospitalizations. ESRD 
patients are highly likely to use the emergency room, averaging between two and three 
visits annually. ESRD hospitalization is expensive and often avoidable, suggesting this to 
be one of the best ways of improving ESRD care going forward, in multiple ways. 
Demographics can help predict many aspects of ESRD care and outcomes. Important 
demographics include age, race/ethnicity, gender, and poverty. Further research is needed 
about the factors predicting ESRD hospitalization, especially unnecessary readmission.  
41 
 
The importance of the key variables which are found in this study is highlighted. 
The independent variables are gender and race/ethnicity, whereas the dependent variables 
are 30-day readmission rates and ESRD-related hospitalization risk, respectively. This 
concludes the literature review.  
Definitions 
End-stage renal disease (ESRD): ESRD is the fifth and final stage of kidney or 
renal disease, at which point the kidneys have ceased to function (Robinson et al., 2016). 
Gender: Gender is the participant’s gender as male or female. Gender will 
function as an independent variable. 
Hemodialysis (dialysis): Dialysis is the process of filtering the bloodstream 
through an external device to filter out waste that the kidneys would normally filter 
(Robinson et al., 2016).  
Race/ethnicity: Race/ethnicity is the biological race or census-indicated ethnicity 
of a person and will take the possible values of Caucasian, Black, Hispanic, Asian, Native 
American/Alaska Native, and Other. Race/ethnicity will function as an independent 
variable.  
United States Renal Data System (USRDS): The USRDS is a comprehensive 
source of information about renal disease that includes a wide array of related topics such 
as disease severity, hospitalizations, pediatric populations, prescription drug use, and 
chronic kidney disease and the transition to ESRD (Collins et al., 2015).  
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30-day readmission: 30-day readmission indicates the number of times a patient 
is re-hospitalized within 30-day of initial ESRD-related hospitalization. 30-day 
readmission will function as a dependent variable.  
Assumptions 
Assumptions represent foundational aspects of the study that cannot be tested and 
must be assumed to be true (Merriam & Tisdell, 2015). There are several assumptions 
underlying the current study. The first is that a quantitative, retrospective cohort study 
can provide meaningful data on ESRD. This assumption is inherent in quantitative 
resources but well supported by the popularity of this approach in medical research. The 
second is that the USRDS provides complete and accurate data regarding patients. The 
number of prior studies that have also used the USRDS dataset supports the validity of 
this assumption. I also assumed that the Medicare and Medicaid data in the USRDS are at 
least a decent proxy for the overall dataset. The study also assumes that demographics 
and other predictors can significantly influence the hospitalization rates of ESRD 
patients. Though other research supports this association, these studies—like the current 
study—cannot prove causation. I also assumed that identifying the populations at greatest 
risk for unnecessary readmission to a hospital setting will have tangible benefits for 
policy and research.  
Scope and Delimitations 
Delimitations represent the soft limitations of a study, those imposed by the 
researcher (Merriam & Tisdell, 2015). Firstly, the current study is delimited to ESRD 
because, as described in the significance section of the literature review, ESRD is a 
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condition of great prevalence and which creates high costs. The current study is delimited 
to studying hospitalization and 30-day readmission. This study will only look at 
hospitalization and 30-day readmission because, as per Matthew et al. (2015) and other 
results in the literature review, reducing the costs associated with ESRD while improving 
care can likely be most effectively done by reducing the number of unnecessary ESRD-
related hospitalizations. The study is delimited to the United States because USRDS data 
are limited to the US context. As with many other USRDS studies, the current study was 
delimited to the Medicare and Medicaid data in the USRDS because—due to the 
government-funded nature of these health insurance programs—their patient data are 
much more fully available compared to data for patients with private insurance. The 
current study did not necessarily generalize well outside of the Medicare and Medicaid 
cohort, but this is a tradeoff that many prior researchers have also deemed acceptable 
because of the significant corresponding benefits of the USRDS as a source of data.  
Significance, Summary, and Conclusions 
Significance 
The current study is significant both in practice and theory. Practically, it is 
important because ESRD is a global health crisis. While ESRD rates have stabilized in 
the United States, they are still increasing with time (Wetmore & Collins, 2016). ESRD 
disproportionately affects vulnerable populations (Mendu et al., 2016), especially those 
of Blacks and Hispanics, and bears a high burden from both an economic (Wang et al., 
2016) and quality-of-life (Raspovic et al., 2017) standpoint. Economically speaking, 
ESRD patients are the most likely to be hospitalized out of patients with any chronic 
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disease, even cancer and heart failure (Lovasik et al., 2016). They are also at significant 
risk of rehospitalization (Matthew et al., 2015). Unplanned rehospitalizations are 
expensive for both the patient and the hospital; therefore, reducing 30-day readmission of 
ESRD patients as a measure of rehospitalization represents an important goal from a 
practical perspective. The results of this study will help hospitals and health 
administrators understand which patients are most at risk of unplanned rehospitalization. 
Doing so may contribute to both social and practical change by providing data necessary 
to develop targeted interventions to reduce 30-day readmission rates in vulnerable 
populations. Reducing 30-day readmission rates for ESRD will improve outcomes for 
both those populations and the hospitals themselves. Theoretically speaking, the study 
addresses a gap in the academic literature characterized by a need for more research to 
determine ways of reducing readmission (Matthew et al., 2015), ESRD hospitalization 
research that considers appropriate contextual and socioeconomic predictors (Newman et 
al., 2016), and more research on race and gender gaps in ESRD hospitalizations (Shah et 
al., 2018).  
Summary and Conclusions 
In summary, ESRD is a serious problem in today’s world. Though there is a lower 
occurrence of ESRD the developed world, it is far from defeated. Thus, while ESRD 
diagnoses are increasing in general, the problem is that minorities—and especially 
minority women—may be at especially high risk for poor outcomes. This problem is 
significant because ESRD is a heavy economic burden not only on patients but on 
caregivers and society (Wang et al., 2016). To address this problem, the purpose of this 
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quantitative nonexperimental historical, correlational design is to determine the extent to 
which gender and race/ethnicity predict 30-day readmission rates after hospitalization for 
ESRD patients. In keeping with this purpose, the study will be guided by three research 
questions: (a) To what extent, if at all, does patient gender predict 30-day hospital 
readmission rate for ESRD patients in the United States? (b) To what extent, if at all, 
does patient race/ethnicity predict 30-day hospital readmission rate for ESRD patients in 
the United States? and (c) Are there any significant interaction impact between gender 
and race/ethnicity in predicting 30-day hospital readmission rate for ESRD patients in the 
United States?  
A significant review of the academic and professional literature reveals the 
importance of 30-day readmission as an outcome and demographics as predictors of 
ESRD-related outcomes. Drawing data from the USRDS and Data.gov historical datasets, 
the current study will examine which of these predictors most significantly drive 
unnecessary ESRD-related hospital readmission. These results have important 
implications in informing interventions to reduce ESRD hospitalization, thereby reducing 
both the personal and societal costs associated with the disease. This section has provided 
an overview of the current study and a review of the literature. Now, in section two of the 
study, the methodological considerations for undertaking it are laid out.  
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Section 2: Research Design and Data Collection 
Introduction 
The purpose of this quantitative study was to determine the extent to which 
gender and race/ethnicity predict 30-day readmission rates after hospitalization for ESRD 
patients. This section of the study outlines the methodology by which it was undertaken. 
In the first section I examine the quantitative methodology and the nonexperimental, 
historical, correlational/retrospective cohort design that I adopted for the study. Secondly, 
I examine various aspects of the research method. These include the population, data 
sources, the operationalization of variables, and the data analysis. Next, I review threats 
to validity and ethical issues. The section concludes with a summary.  
Research Design and Rationale 
The nature of the current study was a quantitative, historical, correlational design. 
Quantitative research is an approach that examines the world from a numerical, objective 
perspective (Bryman, 2016). Quantitative research is aimed at examining issues that can 
be quantified, such as those for which there are existing, validated quantitative 
instruments to measure, or for understanding the nature of the relationships between two 
or more variables (Bryman, 2016). Overall, the greatest strength of a quantitative study is 
that its results are based solely on objective data measured using carefully validated 
instrumentation. The numerical or otherwise closed-ended nature of this type of data also 
means that quantitative research can practically process and analyze large sample sizes 
(Bryman, 2016). Quantitative research creates results that can be generalized and whose 
strength can be measured using statistical techniques such as power analyses and 
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confidence intervals using these larger sample sizes. All of this made the quantitative 
approach a strong fit for the current study because it is used to examine the relationships 
between easily quantified and measured variables. All the predictor and outcome 
variables in the research questions—gender, race/ethnicity, 30-day hospital readmission 
rate, and medicate claims—were either quantitative by nature or easily assessed 
sociodemographic variables. Furthermore, all three of the research questions guiding the 
current study pertained to the nature of the relationship(s) between these variables, and, 
as the next section demonstrates, large datasets were available containing these data. 
The specific research design was that of a historical, correlational design. 
Correlational research is a type of quantitative research that focuses on uncovering the 
correlational or associational relationships between variables (Johnson, 2001). 
Correlational research cannot establish stronger causal links as an experiment can, but 
correlational research has significantly less stringent data collection limitations in 
exchange for this drawback. Rather than creating a controlled experiment in which 
variables are manipulated, the correlational researcher can collect data from a cross-
sectional or historical sample (Johnson, 2001). Historical data are preferable as such data 
tend to be readily available without resource-intensive data collection on the part of the 
researcher and offer large sample sizes when historical repositories of the relevant data 
can be found. Because such historical data exist for the variables under study in the 





The study population for this study was all United States patients who suffer from 
ESRD and have been hospitalized because of their ESRD. For practicality and data 
availability, the study population was further limited to patients whose ESRD 
hospitalizations resulted in Medicare claims and those hospitalized during the period 
2017-2018. Although I placed a special interest on the data for Blacks and Hispanics, this 
study had no racial delimitations. Furthermore, for this research I did not use other 
demographic factors to delimit the population of the study, allowing the use of the full 
range of publicly available data.  
Power Analysis and Sample Size Estimation  
I used G*Power v3.1 software to perform a power analysis and determine the 
necessary minimum sample size for the study (Faul et al., 2009). A statistical power of 
80% is relatively standard and was used (Charan & Biswas, 2013). Similarly, I used a 
medium effect size, as represented by d = 0.5 or f2 = 0.15 (Ferguson, 2009). A 
significance of 0.05 is also a standard value, although it must be noted that this only 
assures statistical significance, not clinical significance. For the ANOVA/t tests, a 
minimum sample of 126 was required. For the regression analysis, a minimum sample 
size of 77 should be achieved. Because the data were drawn from a very large historical 
database, meeting and exceeding these minimum sample sizes presented no difficulty.  
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Sources of Data 
The study's data were drawn from two secondary sources: Data.gov and the 
USRDS. Data for RQ1 to RQ3 were drawn from the dataset available through the 
USRDS. The USRDS is a national registry for data on people with ESRD in the United 
States, funded by the National Institutes of Health, National Institute of Diabetes and 
Digestive and Kidney Diseases. The USRDS is a comprehensive database of all renal 
patients in the United States, although many of the more specialized data are only 
available for patients with Medicare claims. Because data regarding hospitalizations are 
limited to Medicare patients in this dataset, the study drew on the Medicare-only portion 
of the USRDS dataset. The USRDS data is in part available freely for any use through an 
annual report. However, more complete data for research and analysis are also available 
upon request. Therefore, for the present study I requested the use of data for the 2016-
2018 period for Medicare patients and the variables of hospitalization, 30-day 
readmission, race/ethnicity, and gender. All these variables were available in the 
Medicare dataset as per the USRDS website. 
For both sources of data, I carried out all original sampling and data collection 
through the submission of Medicare claims for hospitalization. As a result, there was no 
significant risk of sampling bias or other undesirable sampling effects as, rather than 
random or convenience, the sampling simply included all eligible data points. 
Operationalization of Variables  
The study variables were as follows: 
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Gender: Gender was operationalized as a binary variable recording the 
participant’s gender as male or female. Gender functioned as an independent variable. 
This data was recorded as part of the ESRD records accessed during data collection. 
Race/ethnicity: Race/ethnicity was operationalized as a categorical variable with 
the possible values of Caucasian, Black, Hispanic, Asian, Native American/Alaska 
Native, and Other. Race/ethnicity functioned as an independent variable. This data was 
recorded as part of the ESRD records accessed during data collection. 
30-day readmission: Thirty-day readmission was measured as an ordinal variable 
indicating the number of times a patient is rehospitalized within 30 days of an initial 
ESRD-related hospitalization. Thirty-day readmission functioned as a dependent variable. 
This data was recorded as part of the ESRD records accessed during data collection and 
was gleaned by comparing data points with matching other characteristics.  
Data Analysis 
Prior to any data analysis, I screened the historical data for clear outliers, and 
these were removed so that they did not unduly skew the results. As I used historical data, 
no cleaning of incomplete responses was necessary. All data analysis were carried out 
with the aid of SPSS statistical software in the latest version. The research questions and 
corresponding hypotheses tested for the study were as follows: 
Research Questions and Hypothesis  
RQ1: To what extent, if at all, does patient gender predict 30-day hospital 
readmission rate for ESRD patients in the United States? 
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H01: Patient gender does not predict 30-day hospital readmission rate for 
ESRD patients in the United States. 
H11: Patient gender predicts 30-day hospital readmission rate for ESRD 
patients in the United States to a statistically significant degree. 
RQ2: To what extent, if at all, does patient race/ethnicity predict 30-day hospital 
readmission rate for ESRD patients in the United States? 
H02: Patient race/ethnicity does not predict 30-day hospital readmission rate 
for ESRD patients in the United States. 
H12: Patient race/ethnicity predicts 30-day hospital readmission rate for ESRD 
patients in the United States to a statistically significant degree. 
RQ3: Is there a significant interaction between gender and race/ethnicity in 
predicting 30-day hospital readmission rate for ESRD patients in the United 
States? 
H03: There is not a significant interaction between gender and race/ethnicity 
in predicting 30-day hospital readmission rate for ESRD patients in the United 
States?  
H13: There is a significant interaction between gender and race/ethnicity in 
predicting 30-day hospital readmission rate for ESRD patients in the United 
States?  
In keeping with the split datasets described in the previous section, I also split the 
data analysis. First, the analysis began with simple descriptive statistics to describe both 
datasets. Then, RQ1 through RQ3 were answered with regression analysis. I carried out 
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three individual regression analyses to answer RQ1, RQ2, and RQ3. These analyses used 
a type of regression appropriate to the predictors; this was simple linear regression in 
most cases. To test the hypotheses, I tested the coefficients of regression and r2  values 
for these regression models to see if they differed significantly from zero. Alternately, 
RQ1 could be answered using a different-sample comparative t test. Multiple regression 
involves using both all the relevant predictors as well as their interaction terms. When 
these interaction terms have a coefficient of regression significantly different from zero, 
there is a moderating effect between those two variables (Bolin, 2014). In addition, the 
overall r2 and individual regression coefficients tested the significance of the overall 
combined model and individual predictors within the combined model.  
Before undertaking these tests, I tested the assumptions of the corresponding 
regression models. These assumptions are the normality of the variables, which was 
tested by a Shapiro–Wilk test, homoscedasticity, which I tested through a Breusch–Pagan 
test, the linearity but not perfect collinearity of variables, and the independence of the 
error terms. If one or more of these assumptions were violated, then I sought a more 
appropriate alternate regression technique.  
Threats to Validity 
Validity and reliability are an intrinsic part of any research (Merriam & Tisdell, 
2015). The reliability of a study relates to the accuracy and replicability of its results. In 
this regard, the validity and reliability of the current study was strong. All variables used 
in the study were drawn from historical data, but each holds an intrinsic value rather than 
an attempt to quantify some construct. Furthermore, the data themselves are drawn from 
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a historical, governmental database from which large amounts of data are available. 
Using a governmental database for this study means that any researcher wishing to 
replicate the study could do so by using the same set of USRDS data and analyzing them 
in the same fashion. Therefore, the reliability of the current study should be strong. 
Validity is divided into internal and external validity (Merriam & Tisdell, 2015). 
Internal validity refers to how well the study fits together and answers the questions it set 
out to answer. The current study achieved significant internal validity through careful 
alignment of all the study components in a chain running from the problem to the purpose 
of the research questions to the data collection variables. However, one threat to internal 
validity is that the research design cannot establish causation, only 
association/correlation. This threat was countered by carefully acknowledging the 
correlational nature of the results when reporting them and taking care not to fall into the 
erroneous use of causal language.  
The large sample size afforded by the USRDS dataset, along with the Data.gov 
dataset, offers a strong basis for external validity, as quantitative results gain external 
validity and generalizability through a large sample size. However, one threat to this is 
that the data included were only for Medicare and Medicaid patients. While there is no 
reason to believe this section of the population has fundamentally different ESRD 
outcomes, this still raises whether the results can be generalized to the entire population. 
Nonetheless, so long as the researcher acknowledges this limitation in reporting the data 




The current study is quantitative in nature and involved the use of publicly 
available, de-identified archival data. Therefore, the current study was expected to pose 
minimal ethical concerns for participants as the study does not involve collecting or 
publishing of any data that are not already publicly available. My personal views and 
biases did not color the results, as the study's raw statistical conclusions were presented 
as a part of data analysis and reporting. Based on these statistical results, a reader may 
determine for themself whether my conclusions were valid. Nonetheless, I took care to 
avoid any bias, as I has some personal stake in the study’s outcome because of having 
lost close family members to ESRD.  
Summary 
In summary, the purpose of this study is to determine the extent to which gender 
and race/ethnicity predict 30-day readmission rates after hospitalization for ESRD 
patients. This purpose was addressed through the use of a quantitative nonexperimental 
historical correlational design, also known as a retrospective cohort study. Key study 
variables included gender, race/ethnicity, and 30-day readmission. These data were 
gathered from two different historical databases, the USRDS for the first set and 
Data.gov for the second. These data were readily and publicly available, allowing me to 
easily access them. Data analysis include descriptive statistics and multiple regression. 
The data analysis results served to test the study hypotheses and provide valuable insight 
into the predictors of ESRD-related hospitalization, which can be used to shape 
interventions to improve ESRD hospitalization-related outcomes. This section has laid 
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out the methodological considerations for the current study. Once I completed this study, 




Section 3: Presentation of the Results and Findings 
ESRD continues to be a problem in the United States, with over 120,000 new 
cases in 2014 alone and over 660,000 total cases in treatment (Saran et al., 2017). The 
problem seems to be even worse for certain races/ethnicities, both in terms of incidence 
rate, a higher risk of being affected by ESRD (Crews et al., 2018), and worse treatment 
access (Patzer et al., 2015). In other words, the problem is that minorities,  especially 
minority women, may be at particularly high risk for poor outcomes related to ESRD 
(Collin et al., 2015; Robinson et al., 2016). Given that ESRD takes a heavy economic toll 
not only on patients but on caregivers and society (Wang et al., 2016), it is important to 
identify whether ESRD does continue to disproportionally affect certain groups more 
than others. In knowing this, interventions could target those most affected and therefore 
have the greatest positive impact. Unplanned rehospitalizations are an expensive burden 
that falls on both patients and the hospitals that treat them. Thus, reducing readmission 
rates is important for both practical and altruistic reasons. With the present research I 
aimed to shed light on race and gender's role on ESRD-related rehospitalizations, as this 
is a research gap in the literature.  
In this chapter, I review the research questions and hypotheses followed by a 
discussion of the methodology, research design, and data collection approach. Next, I 
present the descriptive statistics for the variables of interest and the results of several 
regression analyses that were conducted to address the research questions to determine 
the extent to which gender and race/ethnicity predict 30-day readmission rates after 
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hospitalization for ESRD patients. Lastly, I discuss the summaries of the findings and 
discuss the implications of the findings for the present hypotheses.  
Research Questions and Hypotheses 
The present research and data analyses were guided by the following research 
questions and hypotheses:  
RQ1: To what extent, if at all, does patient gender predict 30-day hospital  
readmission rate for ESRD patients in the United States?  
H01: Patient gender does not predict 30-day hospital readmission rate for 
ESRD patients in the United States. 
H11: Patient gender predicts 30-day hospital readmission rate for ESRD 
patients in the United States to a statistically significant degree. 
RQ2: To what extent, if at all, does patient race/ethnicity predict 30-day hospital  
readmission rate for ESRD patients in the United States? 
H02: Patient race/ethnicity does not predict 30-day hospital readmission rate 
for ESRD patients in the United States. 
H12: Patient race/ethnicity predicts 30-day hospital readmission rate for ESRD 
patients in the United States to a statistically significant degree. 
RQ3: RQ3: Is there a significant interaction between gender and race/ethnicity in 




H03: There is not a significant interaction between gender and race/ethnicity 
in predicting 30-day hospital readmission rate for ESRD patients in the United 
States?  
H13: There is a significant interaction between gender and race/ethnicity in 
predicting 30-day hospital readmission rate for ESRD patients in the United 
States?  
Methodology and Research Design  
Rationale for the Present Research Design and Methodology 
I used a quantitative nonexperimental, correlational methodology using historical 
data for the present research. This approach was necessary because random assignment 
was not possible with the demographic variables of interest. In other words, people 
cannot be randomly assigned to be male or female, for example.  
Although causal claims cannot be confidently made with this approach, regression 
analyses could inform both the strength and the direction of the relationships between 
gender, race/ethnicity, and readmission rates for ESRD patients (Gallo, 2015; 
Montgomery et al., 2012). Thus, the independent variables were gender and 
race/ethnicity, whereas the dependent variables were 30-day readmission rates and 
ESRD-related hospitalization risk.  
Validity and Reliability 
The inability to draw causal inferences due to the nonexperimental approach does 
limit the internal validity of the research. In other words, because the variables of interest 
are measured and not manipulated, the research is correlational, and the associations 
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between variables are also inevitably measured and not manipulated (Thompson et al., 
2005). The use of real historical hospital data does increase the reliability and external 
validity of the research, as it is easier to generalize the findings to other real patients. The 
obtained hospital data spans from 2007 to 2017, limiting the reliability and external 
validity of the research by limiting the ability to make inferences about ESRD-related 
hospitalization rates prior to 2007 and after 2017. 
Data Collection, Sample, and Sampling Approach  
As stated, the study population was U.S. patients who suffer from ESRD and have 
been hospitalized because of their ESRD with Medicare claims from the period 2017-
2018. Although I placed a special interest on the data for Blacks and Hispanics, this study 
had no racial delimitations. A minimum sample size of 77 of ESRD patients were 
recruited for this study. 
The data was gathered from two different historical databases: the USRDS for the 
first set and Data.gov for the second. This data was readily and publicly available, 
allowing me easy access. The large, national datasets available ensure that meeting the 
minimum sample size requirements was easily achieved and exceeded. The research 
sample’s gender and race/ethnicity were collected using a survey approach. For 
readmission rates, data was collected by the hospitals and did not require self-reporting 
on the part of the patients.  
For the present study I requested the use of data for the 2016-2018 period for 
Medicare patients and the variables of hospitalization, 30-day readmission, race/ethnicity, 
and gender. All these variables were available in the Medicare dataset as per the USRDS 
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website. The study drew on the Medicare-only portion of the USRDS dataset because 
data regarding hospitalizations were limited to Medicare patients in this dataset. 
Instrumentation 
The data in the USRDS comprised actual health outcomes. Given that the data 
comprised actual health outcomes rather than self-report measures provided by 
participants, the data in the USRDS was itself extracted from claims-based and 
enrollment data obtained from the Centers for Medicare & Medicaid Services. The 
USRDS data is in part available freely for any use through an annual report. However, 
more complete data for research and analysis are also available upon request. 
Results and Analyses 
Descriptive Statistics Analysis 
Before conducting analyses to test the hypotheses, I conducted analyses to obtain 
descriptive statistics for variables of interest: gender, race/ethnicity, and 30-day 
readmission rates after hospitalization. This was done for each of these variables for the 
data from years 2007 to 2017. The descriptive statistics in terms of mean and standard 
deviation can be found in Table 1. In terms of gender differences, the sample of the study 
consisted of two groups, which were male samples and female samples. In terms of 
race/ethnicity differences, the sample of the study consisted of four groups, which were 





Descriptive Statistics for Gender, Race/Ethnicity, and 30-Day Readmission Rates After 
Hospitalization (Percentages). 










2007 M 56.15 43.85 81.99 9.38 5.50 3.13 18.20  
SD 1.72 1.72 13.35 8.90 9.17 4.97 2.19 
2008 M 56.02 43.98 81.72 9.38 5.61 3.29 84.07  
SD 1.69 1.69 13.40 8.92 9.24 5.01 13.97 
2009 M 55.92 44.08 81.26 9.57 5.74 3.43 83.66  
SD 1.66 1.66 13.54 9.08 9.36 5.02 14.10 
2010 M 55.76 44.24 80.82 9.76 5.85 3.57 83.27  
SD 1.62 1.62 13.66 9.23 9.44 5.04 14.20 
2011 M 55.54 44.46 80.46 9.86 5.93 3.75 82.90  
SD 1.58 1.58 13.69 9.29 9.51 5.02 14.23 
2012 M 55.41 44.59 80.19 9.86 5.94 4.00 82.59  
SD 1.55 1.55 13.66 9.28 9.52 5.04 14.20 
2013 M 55.22 44.78 79.96 9.84 5.93 4.27 82.28  
SD 1.52 1.52 13.60 9.21 9.52 5.04 14.13 
2014 M 55.05 44.95 79.93 9.71 5.84 4.52 82.07  
SD 1.46 1.46 13.45 9.15 9.41 5.02 13.99 
2015 M 54.94 45.06 79.85 9.56 5.80 4.78 81.89   
SD 1.45 1.45 13.28 9.08 9.22 5.01 13.83 
2016 M 54.88 45.12 79.56 9.47 5.87 5.10 81.63  
SD 1.43 1.43 13.29 9.02 9.24 5.06 13.83 
2017 M 54.77 45.23 79.57 9.28 5.71 5.45 81.59  





To determine the appropriate analyses, I conducted tests to examine whether 
specific assumptions were met for normality, homoscedasticity, and linearity. To test the 
normality assumption, I plotted the distribution of residuals. The figure revealed a normal 
distribution of residuals, suggesting this assumption was not violated (Figure 1). Two 
additional measures of normality, Skewness and Kurtosis, were also not violated (p = .35 
and p = .81, respectively). I used a different test to examine whether the variability of the 
variable was unequal across the range of values of a second variable that predicts it, 
which revealed that the homoscedasticity assumption was not violated (p = .75). To test 
the linearity assumption, I plotted the residuals against the dependent variable in the 
model (i.e., readmission rates after hospitalization). The residuals for each of the 
predictor variables matched the dependent variable in a linear pattern, suggesting 
linearity was not violated (Figure 2). Given that the linearity assumption was not 
violated, linear regression analyses were used to test the hypotheses.  
Regression Results 
I conducted several regression analyses to address the research questions. I 
conducted one regression using row-wise averages from 2007 to 2017 for each variable 
and separate regression analyses for each year. I included gender and race/ethnicity as 
predictor variables in the model and included readmission rates after hospitalization as an 
outcome variable to test the hypotheses. To test whether there were any significant 
interactions between gender, race/ethnicity, I included the interaction terms of gender and 
race/ethnicity as a predictor in the model.  
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Research Question 1. The first research question was: To what extent, if at all, 
does patient gender predict 30-day hospital readmission rate for ESRD patients in the 
United States? The results of the linear regression for RQ1 is presented in Table 2. The 
results of the regression analysis using row-wise averages from years 2007 to 2017, for 
each variable of interest, revealed three main effects: the percentage of females ( =1.02, 
p < .01) Blacks ( = .08, p < .01), and Hispanics ( = .05, p < .05) in the population, all 
significantly predicted readmission rates after hospitalization. The model was overall 
significant, 𝑅2 = .35, CI [.26, .42], and accounted for 35% of the variance.  
The specific regression results to address RQ1 revealed that the percentage of 
females in the population significantly predicted readmission rates after hospitalization ( 
= 1.02, p < .01). Specifically, higher percentages of females in the population were 
associated with higher readmission rates after hospitalization. Furthermore, looking at the 
relationship between gender and readmission rates after hospitalization revealed that in 
every year until 2015, the percentage of females significantly and positively predicted 




Table 2  
Regression Results Using Row-Wise From Years 2007 to 2017, for Each Variable and 














   




















     R2 = .353** 
     95% CI[.26,.42] 
      
Note. * indicates p < .05; ** indicates p < .01. A significant b-weight indicates the beta-weight and semi-
partial correlation are also significant. b represents unstandardized regression weights; beta indicates the 
standardized regression weights; sr2 represents the semi-partial correlation squared; r represents the zero-
order correlation. LL and UL indicate the lower and upper limits of a confidence interval, respectively. 
 
Research Question 2. The second research question was: To what extent, if at all, 
does patient race/ethnicity predict 30-day hospital readmission rate for ESRD patients in 
the United States? I conducted regression analyses using row-wise averages from the 
years 2007 to 2017 to answer this question. The results of the linear regression for RQ2 
are presented in Table 3. These analyses revealed that the percentage of Blacks and 
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Hispanics in the population both significantly predicted readmission rates after 
hospitalization ( = .08, p < .01 and  = .05, p < .05, respectively). Specifically, higher 
percentages of Blacks and Hispanics in the population were associated with higher 30-
day hospital readmission rate for ESRD patients in the United States. The percentage of 
Whites in the population was not associated with hospital readmission rates, CI [-0.01, 
0.90]. 
Additionally, I ran separate regression analyses for each year from 2007 to 2017, 
with race/ethnicity as a predictor in the model and readmission rates after hospitalization 
as an outcome variable. In 2007, the percentage of Blacks and the percentage of Whites 
were significant predictors of readmission rates after hospitalization. The percentage of 
Hispanics significantly and positively predicted readmission rates in 2008 and from 2014 
to 2017. The percentage of Whites only positively predicted readmission rates in 2007 
and 2008.  
Furthermore, looking at the relationship between race and readmission rates after 
hospitalization revealed that every year until 2015, the percentage of Blacks significantly 
and positively predicted readmission rates. The full regression results for each year for 
RQ2 can be found in Table 3. Based on these results, H02 can be rejected, as 





2008-2017 Regression Analyses of Hypothesized Predictors of Hospital Readmission 
Rates 




      
2008 Female 1.09** [0.37, 1.82] .37**  
 White 0.48* [0.03, 0.94] -.42**  
 Interaction -0.01* [-0.02, -
0.00] 
  
 Black 0.08** [0.03, 0.13] .49**  
 Hispanic 0.05* [0.00, 0.10] .16**  
     R2 = .349** 
     95% CI[.26,.42] 
2009 Female 1.10** [0.35, 1.85] .38**  
 White 0.47 [-0.00, 0.94] -.42**  
 Interaction -0.01* [-0.02, -
0.00] 
  
 Black 0.08** [0.02, 0.13] .48**  
 Hispanic 0.05 [-0.01, 0.10] .16**  
     R2 = .341** 
     95% CI[.25,.41] 
2010 Female 0.99* [0.21, 1.76] .37**  
 White 0.41 [-0.08, 0.89] -.41**  
 Interaction -0.01 [-0.02, 0.00]   
 Black 0.07** [0.02, 0.13] .47**  
 Hispanic 0.04 [-0.01, 0.09] .16**  
     R2= .318** 
     95% CI[.23,.38] 
2011 Female 0.91* [0.13, 1.70] .36**  
 White 0.39 [-0.10, 0.89] -.39**  
 Interaction -0.01 [-0.02, 0.00]   
 Black 0.09** [0.04, 0.14] .48**  
 Hispanic 0.04 [-0.01, 0.09] .12*  
     R2 = .308** 
     95% CI[.22,.38] 
2012 Female 0.81* [0.06, 1.55] .38**  
 White 0.30 [-0.17, 0.78] -.41**  
 Interaction -0.01 [-0.01, 0.00]   
 Black 0.08** [0.03, 0.12] .48**  
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 Hispanic 0.03 [-0.02, 0.08] .14*  
     R2 = .320** 
     95% CI[.23,.39] 
2013 Female 0.92* [0.22, 1.63] .37**  
 White 0.41 [-0.04, 0.87] -.42**  
 Interaction -0.01 [-0.02, 0.00]   
 Black 0.08** [0.04, 0.13] .50**  
 Hispanic 0.04 [-0.00, 0.09] .14*  
     R2 = .336** 
     95% CI[.24,.40] 
2014 Female 0.86* [0.11, 1.61] .36**  
 White 0.39 [-0.09, 0.88] -.40**  
 Interaction -0.01 [-0.02, 0.00]   
 Black 0.10** [0.05, 0.15] .50**  
 Hispanic 0.05* [0.01, 0.10] .13*  
     R2 = .322** 
     95% CI[.23,.39] 
2015 Female 0.74 [-0.01, 1.49] .34**  
 White 0.33 [-0.16, 0.82] -.39**  
 Interaction -0.01 [-0.01, 0.00]   
 Black 0.10** [0.05, 0.14] .46**  
 Hispanic 0.06** [0.02, 0.11] .15**  
     R2 = .289** 
     95% CI[.20,.36] 
2016 Female 0.73 [-0.04, 1.51] .35**  
 White 0.32 [-0.19, 0.82] -.40**  
 Interaction -0.01 [-0.02, 0.00]   
 Black 0.09** [0.05, 0.14] .46**  
 Hispanic 0.06* [0.01, 0.10] .16**  
     R2 = .287** 
     95% CI[.20,.35] 
2017 Female 0.53 [-0.23, 1.29] .35**  
 White 0.18 [-0.33, 0.68] -.42**  
 Interaction -0.00 [-0.01, 0.01]   
 Black 0.10** [0.06, 0.14] .46**  
 Hispanic 0.07** [0.03, 0.12] .19**  
     R2 = .310** 
     95% CI[.22,.38] 
Note. * indicates p < .05; ** indicates p < .01. A significant b-weight indicates the beta-weight 
and semi-partial correlation are also significant. b represents unstandardized regression weights; 
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beta indicates the standardized regression weights; sr2 represents the semi-partial correlation 
squared; r represents the zero-order correlation. LL and UL indicate the lower and upper limits of 
a confidence interval, respectively. 
Research Question 3. The third research question was: Are there any significant 
interaction impact between gender and race/ethnicity in predicting 30-day hospital 
readmission rate for ESRD patients in the United States? To test whether there are any 
significant interactions between gender and race/ethnicity, I conducted regression 
analyses were conducted with the interaction between gender and race/ethnicity as a 
predictor in the model. This interaction was significant,  = -.01, p < .05. The interaction 
was such that at lower levels of females in the population, levels of Whites in the 
population have no significant relationship with hospital readmission rates. However, at 
higher levels of females in the population, fewer (vs. more) Whites in the population are 
associated with higher hospital readmission rates. The interaction between race and 
gender was only significant in 2007, 2008, and 2009. The full regression results can be 
found in Table 4. The regression results for the interaction between gender and 
race/ethnicity in predicting readmission rates for years 2008-2017 can be found in Table 
4. Based on these results, null hypothesis H03 can be rejected, as there was a significant 
interaction between the percentage of females in the population and the percentage of 
Whites in the population, with regards to hospital readmission rates. 
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Table 4  
 











(Intercept) -45.34* [-83.75, -6.92]    
Female 1.16** [0.45, 1.86] 0.91 [0.36, 1.46]  
White 0.51* [0.07, 0.95] 0.91 [0.36, 1.46]  
Interaction -0.01* [-0.02, -0.00] 0.91 [0.36, 1.46]  
Black 0.07** [0.02, 0.12] 0.91 [0.36, 1.46]  
Hispanic 0.05 [-0.00, 0.09] 0.91 [0.36, 1.46]  
     R2 = .354** 
     
95% 
CI[.26,.42] 
      
Note. * indicates p < .05; ** indicates p < .01. A significant b-weight indicates the beta-weight and semi-
partial correlation are also significant. b represents unstandardized regression weights; beta indicates the 
standardized regression weights; sr2 represents the semi-partial correlation squared; r represents the zero-
order correlation. LL and UL indicate the lower and upper limits of a confidence interval, respectively. 
 
Summary 
Section 3 presented the results of the quantitative analysis to test the different 
research questions of the study. The study outcomes can be found in tables and graphs 
with descriptive narratives. I used SPSS for the data analysis. The first information 
presented included in the result section is for the descriptive statistics summaries of the 
study variables. Then, parametric assumption testing results, including normality, 
homoscedasticity, and linearity were discussed. This analysis was followed by the 
discussion of the results of the different regression analyses to address the three different 
research questions of this study. This chapter ended with a summary of the results. 
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Taken together, the results of the different regression analyses have several 
implications for the posed research questions. For RQ1, the regression analysis results 
resulted in the rejection of H01, as gender (i.e., the percentage of females in the 
population) was a significant predictor of hospital readmission rates every year until 
2015.  
For RQ2, the regression analysis results resulted in the rejection of H02, as 
race/ethnicity was a significant positive predictor of hospital readmission rates. 
Specifically, the percentage of Blacks significantly and positively predicted hospital 
readmission rates almost every year. The percentage of Hispanics significantly and 
positively predicted readmission rates in 2008 and from 2014-2017. The percentage of 
Whites only positively predicted readmission rates in 2007 and 2008.  
For RQ3, results of the regression analysis resulted to the partial rejection of H03 
because the interaction between race and gender was significant in 2007, 2008, and 2009. 
Specifically, the interaction impact showed that at lower levels of females in the 
population, levels of Whites in the population have no significant relationship with 
hospital readmission rates. However, at higher levels of females in the population, fewer 
(vs. more) Whites in the population are associated with higher hospital readmission rates. 
The following section, Section 4 concludes this study. Implications of the results 
of the data analysis were discussed in detail in Section 4. Suggestions on how the 
findings may be applied in an organizational setting and a summary of recommendations 




Section 4: Application to Professional Practice and Implications for Social Change 
Introduction 
ESRD is a severe issue in the medical field today. ESRD affects over two million 
people globally (Robinson et al., 2016). One type of treatment for ESRD is hemodialysis, 
an external filtration device that cleanses the patient’s blood instead of the kidney doing 
so. The primary remedy for ERSD is a kidney transplant, but a donor kidney is difficult 
to obtain as there is often a lack of supply to meet the demand, and therefore, the 
problems associated with ESRD lead to frequent emergency department visits and 
hospital readmissions (Robinson et al., 2016). ESRD patients must contend with other 
issues such as socioeconomic and demographic differences. A major concern is racism, 
particularly for Black people, which various studies have shown predict worse than 
average ESRD outcomes, indicating that a psychosocial element may be associated with 
treatment (Savage, 2017). The purpose of this quantitative nonexperimental, historical, 
correlational design was to determine the extent to which gender and race/ethnicity 
predict 30-day readmission rates after hospitalization for ESRD patients. This section will 
look at the interpretation of the findings as they relate to the literature, limitations, 
recommendations, and implications for social change. It will close with a conclusion. 
Theoretical Foundation 
I selected a theoretical foundation to guide and contextualize this research. This 
framework was a theory of the determinants of avoidable readmissions in ESRD by 
Matthew et al. (2015). The theory illustrates the characteristics that cause preventable 
hospital readmissions for the disease. These characteristics can be length of hospital stay, 
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quality of the hospital, its dialysis facility, the doctors and care providers, and how the 
treatment is paid for. However, this study only included one aspect of the theory. This 
aspect was the role of patient characteristics. As the innumerable factors that cause 
avoidable readmission are interconnected, it is important to understand the relationship 
between variables (Matthew et al., 2015). Through the focus on demographic and 
socioeconomic variables, hospitals may be provided with increased resources to mitigate 
this problem, thereby allowing this theory to expand.  
Interpretation of the Data 
I used regression analysis to understand the relationships between the variables 
and readmission rates of ESRD patients (see Gallo, 2015; Montgomery et al., 2012). The 
study results are as follows: I rejected the null hypothesis of RQ1 and found that gender, 
in this case the percentage of females, was a significant predictor of hospital readmission 
rates in every year into 2015. I also rejected the null hypothesis for RQ2 as race/ethnicity 
was found to have a significant positive predictor of hospital readmission rates. Of the 
races, Blacks have the highest readmission rate, with Hispanics also maintaining high 
rates. Lastly, I rejected the null hypothesis of RQ3 as there was zero correspondence 
between race and gender in the years 2007, 2008, and 2009. 
Interpretation of the Findings 
Research Question 1 
The first research question asked to what extent, if at all, a patient’s gender 
predicts 30-day hospital readmission rate for ESRD patients in the United States. After 
regression analysis, the study found a statistically significant relationship between 
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females in the population and readmission rates after hospitalization, thereby rejecting the 
null hypothesis. More specifically, males are much less likely to have high readmission 
rates when compared to females in every year until 2015. Thus, there was a statistically 
significant relationship between gender and readmission rates after hospitalization.  
The results of the relationship between gender and readmission rates are difficult 
to dispute as the sample of 77 Medicare patients came from archived sources. A random 
assignment was not applied because of the need to select the chosen demographic 
variables. Regression analysis was the strongest analysis approach to determine the 
relationship between gender and readmission rates due to the targeted sample (see Gallo, 
2015; Montgomery et al., 2012). 
In a study by Chan et al. (2017), the authors examined predictors for 30-day 
readmission rates for ESRD and found gender to be a significant independent predictor. 
This is supported in a separate study by Chan (2017), which found that age, female 
gender, and comorbidities all influence 30-day readmission rates. Neugarten and 
Reckelhoff (2015) studied kidney disease across various animals and found that ESRD 
progressed more quickly in males than females. The authors suggested that sex hormones 
rather than the physical structure of genders predicted differences with the disease. 
However, the suggestion that it is sex hormones rather than gender itself goes against this 
study's results as the results indicated a statistically significant relationship between the 
ESRD readmission rates and gender. This is not to discount Neugarten and Reckelhoff 
(2015), but their study results focused on animals rather than humans. 
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This study aligned with the theoretical framework of Matthew et al. (2015), which 
highlighted that patient characteristics represent an important factor in ESRD. Matthew et 
al. suggested that by studying single demographics, there could be increased knowledge 
of the broader issues of the disease. This was certainly the case with RQ1, as it showed 
that women had higher rates than men, yet remained underserved in terms of treatment. 
These results could help reduce avoidable readmissions due to a lack of treatment from a 
healthcare provider. 
Research Question 2 
The second research question asked to what extent, if at all, a patient’s 
race/ethnicity predicts 30-day hospital readmission rate for ESRD patients in the United 
States. The study found a significant relationship between readmission rates and 
ethnicity, specifically among Black and Hispanic patients. Black individuals, however, 
had the highest rate of ESRD, with Hispanics coming in second, yet both were much 
more significant when compared to Whites.  
In general, diseases such as diabetes and hypertension differ among varying 
ethnic groups (Webster et al., 2017). This information can also be applied to ESRD and 
other related factors. Lovasik et al. (2016) noted that not only does race predict ESRD 
outcomes, but it can also affect other predictors. An example of this would be a dietary 
acid load, which can predict the development of kidney disease and its progression 
among different races and ethnicities, in this case, Whites and Blacks (Crews et al., 
2018). Crews et al. (2018) pointed out that through the various stages of renal disease 
among racial groups, Black people had a disadvantage with higher rates. 
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As noted earlier, race can be linked to different socioeconomic conditions. In a 
study by Nee et al. (2017), the authors noted that care availability differs by 
demographics. Patients who have easy access to nephrology before reaching ESRD had 
lower mortality and morbidity rates (Gillespie et al., 2015). Therefore, those of different 
races need to receive the same treatment as those in other socioeconomic groups. Nee et 
al. (2017) studied a sample of 739,537 patients from 2007-2012 and found that those in 
poverty who have Medicare and Medicaid eligibility were less likely to undergo pre-
ESRD nephrological care, especially Blacks and Hispanics when compared to Whites. 
Therefore, Gillespie et al. (2015) noted that this put impoverished and racial minorities at 
a greater risk for ESRD mortality than Whites. This risk can also affect employment 
status and insurance availability. Cervantes et al. (2018) noted that those with access to 
dialysis regularly could decrease the risk of mortality up to 14 times compared to 
emergency access later.  
Newman et al. (2016) examined racial differences in the hospitalization of 
patients who wait on kidney transplants. The study had a sample of 24,582 patients 
between 2005 and 2009. The results found that hospitalized patients were less likely to 
receive a kidney transplant, and, unfortunately, Blacks and Hispanics had higher rates of 
hospitalization than Whites. The higher rate of hospitalization creates an uneven playing 
field for those who need kidney transplants.  
However, not all differences regarding race and ethnicity can be placed squarely 
on treatment. Savage (2017) found that Black ESRD patients were less likely to adhere to 
treatment guidelines than other races and ethnicities. One reason for this might be 
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perceived racism in the healthcare system, as participants stated that they felt everyday 
racism with the medical community. This everyday racism diminishes the participants’ 
willingness to adhere to guidelines for ESRD treatment. When coupled with the 
likelihood of increased chances of ESRD and reduced healthcare access, this creates a 
negative incentive to receiving and maintaining positive treatment. 
Like RQ1, the theoretical framework was relevant to this result as race can affect 
ESRD treatment. These broader principles can reveal discrepancies such as differences in 
healthcare access among varying demographics and socioeconomic statuses. This affects 
the way that healthcare is received (Newman et al., 2016). Webster et al. (2017) pointed 
out that differences among groups can influence ESRD through differing contexts. 
Typically, avoidable readmissions can be reduced through treatment; however, when 
there is a failure of the healthcare provider or self-care, treatment can be worsened. 
Therefore, Matthew et al.’s (2015) framework holds that the narrow results may link to 
broader issues. 
Research Question 3 
RQ3 asks if there is a significant interaction between gender and race/ethnicity in 
predicting 30-day hospital readmission rate for ESRD patients in the United States. Using 
regression analysis, I focused on gender and race/ethnicity as predictors in the model. 
There was found to be a significant relationship between both variables; however, there 
were some inconsistencies. At lower levels of females in the population, levels of whites 
had no relationship with hospital readmission. However, more females versus more 
Whites were associated with higher hospitalization rates. The interaction between race 
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and gender only occurred in 2007, 2008, and 2009. Nevertheless, these results were 
enough to reject the null hypothesis. 
The results of this research question were not surprising. As RQ1 through RQ3 
were all found to have statistically significant relationships, it would be shocking to find 
no correlation between the variables. Additionally, the literature review agreed with the 
previous research questions, thus further validating the results.  
For example, Patzer et al. (2015) found that impoverished patients are less likely 
to be referred for kidney transplants. Additionally, Nee et al. (2017) found that those in 
poverty are less likely to have pre-ESRD nephrology than those with money and that 
those in poverty, as measured by Medicare and Medicaid eligibility, were less likely to 
receive care as regards to race for Blacks and Hispanics relative to Whites. Gillespie et al. 
(2015) summed this up in their study that showed impoverished and racial minorities are 
at risk for 1st-year mortality. Lastly, Shah et al. (2018) found that women are 6% less 
likely to be given information about kidney transplants than men. Therefore, the 
combination of these studies reinforces the results of the RQ3. Most importantly, the 
results of the RQ3 strengthen the theoretical framework. Each response to the research 
question showed that smaller individual variables could reflect broader issues when 
regarding ESRD. Each one of these variables provides further opportunity for future 
research. 
Limitations 
This study had numerous limitations. The first limitation was that the data was 
secondary. No data was gathered by me, meaning that I had no control over the data 
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collection process and how precise it was. This process left me to assume that the data 
was accurate while potentially leaving the door open for possible data errors that cannot 
be predicted. The second limitation also regarded data. Although there is a large sample 
size that offered strong external validity, the gathered data was only for Medicare and 
Medicaid patients. The use of only Medicare and Medicaid patients limits the 
generalization of the results to the full population. The third limitation was that only 
public data sets were utilized in the study. Private data sets may offer different outcomes, 
especially regarding race and gender. The final limitation was that the final research 
question did not explain why disparities may exist between gender and race/ethnicity. 
While there was a significant relationship between the variables, it only occurred during 
certain years. Without further research, it is unknown why these years were more 
important than others. 
One issue with the research's internal validity was that there was an inability to 
create patient inferences due to the nonexperimental approach. The variables of interest 
are measured and unmanipulated, leaving the research correlational and the associations 
between the variables uninfluenced. Additionally, the use of real historical hospital data 
did increase the reliability and external validity of the investigation, as it makes it easier 
to generalize the results to other patients. However, due to the study's historical 
timeframe, the reliability and external validity were limited only to the time selected. 
Recommendations 
This study's results have yielded recommendations that I propose for future 
research, practical recommendations that could be used to improve health outcomes, and 
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implications for social change. Much like the theoretical framework suggested, 
concentrating on smaller aspects of ESRD patients can provide insight into the bigger 
picture. The new emphasis on gender, race, and socioeconomic status during diagnosis 
and treatment can reduce complications. Blacks and Hispanic patients and those with 
reduced resources should be provided with the appropriate knowledge and treatment from 
the beginning of the diagnosis. A renewed emphasis on studying these demographics 
could provide further insight into the phenomenon. Further research could focus on how 
these demographics are treated and what information is given to them throughout their 
medical diagnosis and treatment. Issues regarding race can further be broken down to 
better understand how differences affect patients throughout the treatment process. Also, 
socioeconomic conditions mixed with geographic locations could provide a better 
understanding of how a lack of resources and availability affects ESRD patients. 
Other recommendations for future research would be to replicate the current 
study, but include more data sets, both publicly available and those created for an 
individual focus. The result of a study like this could help contribute to the external 
validity of this study. Data can also come from various countries to help determine the 
effectiveness of treatment within the United States. Additionally, variables such as 
education and age can be used to understand the phenomenon further. Like the theoretical 
framework stated, focusing on smaller subsets can provide greater insight. Finally, a 
change in research design, such as quantitative to qualitative, can provide greater 
information. Understanding the process from the doctors' or patients' point of view can 
help understand the deficits within the treatment process. 
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A shift to a qualitative study could also explore ESRD. Understanding the 
patients’ and doctors’ points of view could shed light on the phenomenon in ways a 
quantitative methodology just could not. For instance, it would be interesting to compare 
demographics in relation to the care that they receive. This would provide first hand 
knowledge of any discrepancies of treatment between races. Another study could 
qualitatively explore what knowledge and education the patients receive post discharge. 
Doing so, may indicate ways in which ESRD education can be improved. 
Implications for Positive Social Change 
This study yielded a variety of options for positive social change. Primarily 
doctors and healthcare providers can place a much-needed emphasis on these highlighted 
groups which can now be diagnosed and treated with the appropriate amount of attention. 
By treating these patients early and often, there could be a less financial burden on the 
patients and institutions and an increased lifespan in early access to get on a kidney 
transplant list. An increased lifespan strengthens families and reduces patient stress. 
A renewed focus on providing appropriate treatment, knowledge and literature can also 
help mitigate readmission rates. Knowing that women have a higher readmission rate 
allows doctors and specialists to place more emphasis on ESRD during the patient’s 
initial visits. More emphasis could be placed on preventative measures and early 
treatment, such as dialysis, to help reduce readmission rates. Additionally, it would 
behoove both the doctor and the patient to screen early and often for ESRD, especially as 
they get older. Women could also be made more aware of the likelihood that they could 
be diagnosed with ESRD. Patients could be educated on high blood pressure, diabetes 
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and other diseases which may relate to ESRD. Literature, such as pamphlets, can be 
distributed early and often highlights the importance and dire consequences of the 
disease. This knowledge could then be used for preventative measures to help mitigate 
and reduce the likelihood of contraction. Women are up against barriers that prevent them 
from receiving the same treatment and knowledge as men. By focusing in the future on 
women’s treatment, this discrepancy can be rectified. Women could be given more 
knowledge and access, thereby reducing mortality rates. 
Conclusion 
The purpose of this quantitative nonexperimental historical, correlational design 
was to determine the extent to which gender and race/ethnicity predict 30-day 
readmission rates after hospitalization for ESRD patients. The study also examined 
interactions between these predictors on the overall risk of ESRD-related hospitalization. 
The study found that gender and race can all be predictors of ESRD hospitalization and 
therefore readmissions. Future research should further expand the data to understand 
other variables, and practical implications should focus on giving these groups the 
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